Method for controlling the alkaloid content of tobacco

Abstract

The present invention provides a method for modulating the alkaloid content of a plant (e.g., a tobacco plant), the method comprising modifying the plant by modulating the activity or expression of galactose-1-phosphate uridyltransferase. The present invention also provides plants obtainable according to the present invention, as well as the use of galactose-1-phosphate uridyltransferase to modulate the alkaloid content of tobacco cells, plants, plant propagation material, harvested leaves, processed tobacco, or tobacco products.

Description

[Technical field]

[0001] The present invention relates to a method for modulating the alkaloid content of a plant or part thereof or a cell or cell culture. The present invention also extends to a method for modulating the expression and / or activity of a polypeptide that modulates the alkaloid content in a plant. Alternatively, the present invention provides a method for modulating the expression and / or activity of a gene encoding a polypeptide that modulates the alkaloid content in a plant. The present invention also extends to constructs that can be used to modulate the polypeptide. The present invention further relates to plant cells and plants modified to achieve modulation of the alkaloid content. The present invention also relates to the use thereof in tobacco industry products, including harvested leaves and combustible smoking articles, processed from such modulated plants. [Background technology]

[0002] Alkaloids are a group of naturally occurring compounds that contain primarily basic nitrogen atoms and are produced by a wide variety of organisms, including bacteria, fungi, plants and animals.

[0003] Alkaloids can be classified according to the similarity of the carbon skeleton, for example, indole-like, isoquinoline-like, and pyridine-like. Pyridine derivatives are a class of monomeric alkaloids, which includes simple derivatives of pyridine, polycyclic fused and non-fused pyridine derivatives, and sesquiterpene pyridine derivatives. Examples include nicotine, nornicotine, pseudooxynicotine, anabasine, myosmine, and anatabine.

[0004] Most of the known biological functions of alkaloids are defense-related. Neuroactive molecules such as caffeine, cocaine, morphine and nicotine act as defense compounds against invading predators. The accumulation of these alkaloids is the result of signaling cascades that monitor gene expression, enzyme activity and alkaloid concentrations. Fine-tuning the alkaloid content in plants involves negative feedback loops and degradation pathways.

[0005] Nicotine occurs naturally in several plants, but is found at the highest levels in tobacco plants. Cultivated tobacco produces 2-4% of the alkaloids by total dry weight. Nicotine is produced in wild and cultivated Nicotiana species and plays an important role in plant defense against herbivores and insects (Voelckel et al. (2001) Oecologia 127(2): 274-280, incorporated herein by reference). Nicotine accounts for approximately 90% of the total alkaloid content. The remaining 10% of the alkaloid pool is made up of the mostly structurally related compounds nornicotine, anatabine, anabasine, and pseudooxynicotine (PON).

[0006] The regulation of alkaloid content in tobacco is complex. Several factors, including genotype, environment, fertilization, and agricultural practices (e.g., topping), affect alkaloid levels in tobacco plants. Several key regulators of nicotine biosynthesis have been well characterized, for example, putrescine N-methyltransferase (PMT), which plays a pivotal role in this pathway, is activated by members of the ethylene responsive factor (ERF) superfamily, the largest family of transcription factors in the tobacco genome (Rushton et al. (2008) Plant Physiol. 147(1): 280-295, incorporated herein by reference).

[0007] Tobacco pyridine alkaloids are precursors of tobacco-specific nitrosamines (TSNAs) formed during curing of leaves after harvest. The four major TSNAs found in cured tobacco leaves are N'-nitrosonornicotine (NNN), N'-nitrosoanatabine (NAT), N'-nitrosoanabasine (NAB), and 4-(methyl nitrosamino)-1-(3-pyridyl)-1-butanone (NNK). During curing of leaves after harvest, reactions between pyridine alkaloids and nitrosated species lead to the formation of TSNAs. PON likely serves as a direct precursor in the synthesis of the TSNA NNK (Bush et al., 2001, incorporated herein by reference). Reducing the production and accumulation of TSNAs is of great importance: the CYP82E family of nicotine demethylase genes is one of the major regulators of the conversion of nicotine to nornicotine, and altering its activity or accumulation may result in reduced NNN levels.

[0008] As described in the Examples, the inventors sought to investigate genes involved in alkaloid and / or TSNA precursor synthesis with the aim of regulating alkaloid content in plants, e.g., reducing TSNA content in tobacco. [Prior art documents] [Non-patent literature]

[0009] [Non-Patent Document 1] Voelckel et al. (2001) Oecologia 127(2): 274-280 [Non-Patent Document 2] Rushton et al. (2008) Plant Physiol. 147(1): 280-295 [Non-Patent Document 3] Bush et al., 2001 Summary of the Invention [Means for solving the problem]

[0010] Surprisingly, it has been found that the alkaloid content and / or TSNA content or TSNA precursor content of a plant can be regulated by regulating the activity or expression of galactose-1-phosphate uridyltransferase. The gene(s) taught herein, such as Nitab4.5_0002825g0060.2, are regulators of alkaloid and TSNA precursor content in cultivated tobacco. In particular, the gene(s) taught herein, such as Nitab4.5_0002825g0060.2, are regulators of alkaloid content in cultivated tobacco. Nitab4.5_0002825g0060.2 encodes the galactose-1-phosphate uridyltransferase according to the present invention. Homologs of Nitab4.5_0002825g0060.2 are provided in Table 1.

[0011] According to the present invention, the alkaloid content can be controlled to produce tobacco industry products with commercially desirable traits desired by consumers of the tobacco industry products. In some cases, consumers may desire products with low levels of alkaloid content. In some cases, consumers may desire products with low levels of TSNA precursors.

[0012] The present invention may be particularly useful in the field of plant molecular agriculture, where plants (such as tobacco and other Nicotiana species) are used for the production of proteins, peptides and metabolites, for example for the production of therapeutics and pharmaceuticals, such as antibiotics, virus-like particles or neutraceuticals or small molecules. Tobacco has been used for the development of HIV-neutralizing antibodies in an EU-funded project called PharmPlant, and Medicago, Canada has worked on a tobacco-based platform for the production of virus-like particles for influenza vaccine production.

[0013] Thus, plants according to the invention can be used for molecular agriculture to reduce or eliminate the presence of nicotinic alkaloids. The use of low nicotine plants or rootsocks would be beneficial in molecular agriculture and would reduce downstream processing costs associated with purification.

[0014] The present inventors have surprisingly determined a method for regulating (e.g., decreasing) the alkaloid content of a plant (e.g., a tobacco plant) by regulating (e.g., decreasing) the activity or expression of galactose-1-phosphate uridyltransferase. The alkaloid content (e.g., the content of one or more of nicotine, nornicotine, PON, anabasine, anatabine or myosmine, suitably the content of one or more of nicotine, nornicotine, PON, anabasine or anatabine) of a plant (e.g., a tobacco plant) can be decreased by decreasing the activity or expression of galactose-1-phosphate uridyltransferase, or increased by increasing the activity or expression of galactose-1-phosphate uridyltransferase.

[0015] Prior to the present invention, it was not known that modulation of galactose-1-phosphate uridyl transferase activity or expression as described herein could be used to modulate alkaloid content, or to modulate TSNA precursor content, in particular nornicotine, PON, anabasine and / or anatabine content.

[0016] The present invention provides a method for modulating (e.g., reducing) the alkaloid content of a tobacco plant or part thereof, or a tobacco plant cell, comprising modifying the plant or plant cell by modulating (e.g., reducing) the activity or expression of galactose-1-phosphate uridyltransferase.

[0017] In another aspect, the present invention provides a method for modulating (e.g., reducing) the content of tobacco-specific nitrosamines (TSNAs) or precursors of TSNAs in a tobacco plant or plant part thereof, or a tobacco plant cell, comprising modifying the plant or plant cell by modulating (e.g., reducing) the activity or expression of galactose-1-phosphate uridyltransferase.

[0018] In another aspect, there is provided a method of producing a plant or part thereof, cell or cell culture, plant propagation material, leaf, cut harvested leaf, treated leaf or cut treated leaf having modulated (e.g. reduced) alkaloid content, the method comprising modifying the plant or cell culture to modulate the activity or expression of galactose-1-phosphate uridyltransferase.

[0019] In another aspect, the present invention provides the use of at least one gene encoding galactose-1-phosphate uridyltransferase for modulating the alkaloid content of a tobacco cell or a tobacco plant or part thereof.

[0020] Suitably, the galactose-1-phosphate uridyltransferase is a) may comprise the amino acid sequence shown in SEQ ID NO: 3, or a functional variant or a functional fragment or an orthologue of SEQ ID NO: 3, or a sequence having at least 80% identity to SEQ ID NO: 3, or a homologue of SEQ ID NO: 3, or b) may be encoded by a nucleotide sequence as set forth in SEQ ID NO: 1 or 2, or a functional variant or functional fragment or orthologue of SEQ ID NO: 1 or 2, or a nucleic acid sequence having at least 80% identity to SEQ ID NO: 1 or 2, or a homologue of SEQ ID NO: 1 or 2.

[0021] Suitably, the alkaloid content is modulated (e.g. reduced) compared to a plant or cell culture that has not been modified to modulate the activity or expression of galactose-1-phosphate uridyl transferase.

[0022] In another aspect, the invention provides a tobacco plant or part thereof, or a tobacco cell or cell culture, that has been modified to modulate (e.g., decrease) the activity or expression of galactose-1-phosphate uridyltransferase, and the tobacco plant or part thereof, or the tobacco cell or cell culture has a reduced content of alkaloids and / or TSNA precursors compared to the unmodified plant or unmodified cell or cell culture.

[0023] In a further aspect, the present invention provides plant propagation material obtainable (e.g. obtained) from a plant according to the invention or from a plant or a cell or cell culture produced by a method or use according to the invention.

[0024] Suitably, the alkaloid content of the plant may be reduced compared to a plant or cell culture that has not been modified to modulate the activity or expression of galactose-1-phosphate uridyltransferase.

[0025] Suitably, the content of one or more alkaloids selected from nicotine, nornicotine, PON, anabasine, myosmine and anatabine may be adjusted (e.g. reduced), preferably the content of nicotine, nornicotine and / or PON is adjusted (e.g. reduced).

[0026] Suitably the nicotine content may be reduced.

[0027] In one aspect, the present invention provides the use of a tobacco plant or part thereof, or a tobacco cell or cell culture according to the present invention, or a plant produced according to the present invention, for breeding plants.

[0028] In another aspect, the present invention provides the use of a tobacco plant or part thereof, or a tobacco cell or cell culture according to the present invention, or a plant produced by a method according to the present invention, for the manufacture of a product.

[0029] In another aspect, the present invention provides the use of a tobacco plant or part thereof according to the present invention, or a plant produced by a method according to the present invention, for producing a crop.

[0030] In another aspect, the present invention provides the use of a tobacco plant or part thereof according to the present invention, or a plant produced by a method according to the present invention, for producing leaves.

[0031] In one aspect, the present invention provides harvested leaves, which may be obtained from a plant according to the invention, or from a plant propagated from propagation material according to the invention, or may be obtained from a plant obtained by a use according to the invention, or may be obtained from a plant produced by a method according to the invention.

[0032] Suitably, the harvested leaves of the plant may be cut harvested leaves.

[0033] In one aspect, the present invention provides a method for producing a method for treating a cancer cell comprising: Obtainable (e.g. obtained) from a plant obtainable from the use according to the invention; can be obtained (e.g. obtained) by treating a plant according to the present invention, obtainable (e.g. obtained) from a plant propagated from plant propagation material according to the invention; or can be obtained (e.g. obtained) by processing harvested leaves of a plant according to the invention, or can be obtained (e.g., obtained) from a plant produced by a method according to the invention Treated leaves, preferably treated tobacco leaves, preferably non-viable treated tobacco leaves, are provided.

[0034] Suitably, the treated leaves may be treated by drying, fermenting, pasteurising or a combination thereof.

[0035] Suitably the treated leaves may be cut treated leaves.

[0036] In one aspect, the present invention provides a cured tobacco material made from a plant or part thereof according to the present invention, or from harvested leaves according to the present invention, or from treated leaves according to the present invention.

[0037] In another aspect, the present invention provides a tobacco blend comprising the dried tobacco material according to the present invention.

[0038] In one aspect, the present invention provides a method for producing a method for treating a cancer cell comprising: A tobacco plant or part thereof or a tobacco cell or cell culture according to the present invention, A tobacco plant or part thereof propagated from the tobacco plant propagation material according to the present invention; Harvested leaves of the plant according to the invention, Treated leaves according to the invention, The present invention provides a tobacco industry product prepared from

[0039] Suitably, the tobacco product may be a combustible smoking article.

[0040] Suitably, the tobacco product may be a smokeless tobacco product.

[0041] Suitably, the tobacco product may be a non-combustible aerosol delivery system, such as a tobacco heating device or an aerosol generating device.

[0042] In another aspect, the present invention provides a combustible smoking article, a non-combustible aerosol delivery system, a smokeless tobacco product, or a tobacco heating device comprising a plant or part thereof or an extract thereof (e.g., a tobacco extract) according to the present invention, or a tobacco cell culture according to the present invention, or a dried tobacco material according to the present invention, or a tobacco blend according to the present invention.

[0043] In one aspect, the present invention relates to the use of a nucleotide sequence encoding a galactose-1-phosphate uridyltransferase protein for the selection of plants having modulated (e.g., reduced) alkaloid content and / or modulated (e.g., reduced) TSNA or precursor to TSNA content, the nucleotide sequence comprising: a) encoding the amino acid sequence shown in SEQ ID NO: 3, or a functional variant or a functional fragment or an orthologue of SEQ ID NO: 3, or a sequence having at least 80% identity to SEQ ID NO: 3, or a homologue of SEQ ID NO: 3, or b) comprising a sequence as set forth in SEQ ID NO: 1 or 2, or a functional variant or a functional fragment or an orthologue of SEQ ID NO: 1 or 2, or a nucleic acid sequence having at least 80% identity to SEQ ID NO: 1 or 2, or a homologue of SEQ ID NO: 1 or 2; The above uses are provided.

[0044] In another aspect, the present invention provides a method for producing a composition comprising: a) encoding the amino acid sequence shown in SEQ ID NO: 3, or a functional variant or a functional fragment or an orthologue of SEQ ID NO: 3, or a sequence having at least 80% identity to SEQ ID NO: 3, or a homologue of SEQ ID NO: 3, or b) comprising a sequence as set forth in SEQ ID NO: 1 or 2, or a functional variant or a functional fragment or an orthologue of SEQ ID NO: 1 or 2, or a nucleic acid sequence having at least 80% identity to SEQ ID NO: 1 or 2, or a homologue of SEQ ID NO: 1 or 2 A plant mutant carrying a genetic variation in a nucleotide sequence, The genetic mutation regulates (e.g., reduces) the activity or expression of galactose-1-phosphate uridyltransferase, and the mutant plant has a regulated (e.g., reduced) alkaloid content and / or a regulated TSNA or TSNA precursor content compared to a comparable plant that does not carry the genetic mutation.

[0045] In another aspect, the present invention provides progeny or seeds of the mutant plant carrying the genetic mutation according to the present invention.

[0046] In one aspect, the present invention provides a method for producing a method for treating a cancer cell comprising: a) encoding the amino acid sequence shown in SEQ ID NO: 3, or a functional variant or a functional fragment or an orthologue of SEQ ID NO: 3, or a sequence having at least 80% identity to SEQ ID NO: 3, or a homologue of SEQ ID NO: 3, or b) comprising a sequence as set forth in SEQ ID NO: 1 or 2, or a functional variant or a functional fragment or an orthologue of SEQ ID NO: 1 or 2, or a nucleic acid sequence having at least 80% identity to SEQ ID NO: 1 or 2, or a homologue of SEQ ID NO: 1 or 2 Harvested leaves, processed leaves, or cured tobacco material produced from a plant containing an alteration in a nucleotide sequence, The modification regulates (e.g., reduces) the activity or expression of galactose-1-phosphate uridyltransferase, and the plant provides harvested leaves, processed leaves, or cured tobacco material having a regulated (e.g., reduced) alkaloid content and / or regulated TSNA or TSNA precursor content compared to a comparable plant that does not possess the modification in the galactose-1-phosphate uridyltransferase.

[0047] In one aspect, in addition to at least one galactose-1-phosphate uridyltransferase, the activity or expression of at least one Nic1 ERF gene (e.g., any one or more of those in FIG. 6, SEQ ID NOs: 7-10) and / or at least one Nic2 ERF gene (e.g., any one or more of those in FIG. 7, SEQ ID NOs: 11-14) is modulated. Suitably, the at least one Nic1 ERF and / or Nic2 ERF gene may comprise a mutation that reduces its expression and / or activity. In one aspect, in addition to modulating (e.g., decreasing activity and / or expression) at least one galactose-1-phosphate uridyltransferase, the activity of ERF199 (e.g., at least one of SEQ ID NOs: 7-10) is modulated (e.g., decreased). In one aspect, in addition to the modulation (e.g., reduced activity and / or expression) of at least one galactose-1-phosphate uridyl transferase, the activity of ERF189 (e.g., at least one of SEQ ID NOs: 11-14) is modulated (e.g., decreased). In one aspect, in addition to the modulation (e.g., reduced activity and / or expression) of at least one galactose-1-phosphate uridyl transferase, the activity of ERF199 (e.g., at least one of SEQ ID NOs: 7-10) and ERF189 (e.g., at least one of SEQ ID NOs: 11-14) is modulated (e.g., decreased). Exemplary sequences of ERF199 and ERF199 are provided in Figures 8-45 (SEQ ID NOs: 7-14). See also International Publication No. WO2018237107, which is incorporated herein by reference in its entirety. [Brief description of the drawings]

[0048] Embodiments of the invention will now be described, by way of example only, with reference to the accompanying drawings, in which: [Figure 1]Figure 1 shows alkaloid content of plants targeted with VIGS constructs of Nitab4.5_0002825g0060.2. Graphs are representative of two biological replicates (N=12) analyzed by one-way ANOVA and Tukey's multiple comparison post-hoc test. Values ​​are shown as mean ± SEM. Asterisks indicate statistical significance with P values ​​less than or equal to 0.05. Pyridine alkaloids: nicotine, nornicotine, and pseudooxynicotine (PON). [Diagram 2] Figure 1 shows the measured endpoint absorbance values ​​(340 nm) for the production of β-NADPH over a 60 minute reaction with 1.7 μg Nitab4.5_0002825g0060.2 enzyme or 0.5 μg positive control enzyme (recombinant human galactose-1-phosphate uridyltransferase, MyBiosource, MBS143204) in the presence of 0.67 mM uridine 5'-diphosphoglucose and 1.3 mM galactose 1-phosphate. The results of the control reactions are also shown on the same graph, showing that the reaction is dependent on uridine 5'-diphosphoglucose and galactose 1-phosphate. Both MBP and no enzyme controls (negative) have limited activity. The commercial positive control shows >5-fold higher activity per microgram of protein in this assay, while the Nitab4.5_0002825g0060.2 enzyme (labeled T4372) shows reliable substrate-dependent activity. Error bars are standard deviations from four replicates. [Diagram 3] FIG. 1 shows the genomic sequence of Nitab4.5_0002825g0060.2 (SEQ ID NO:1). [Figure 4] FIG. 2 shows the coding sequence of Nitab4.5_0002825g0060.2 (SEQ ID NO:2). [Diagram 5] FIG. 1 shows the amino acid sequence of Nitab4.5_0002825g0060.2 (SEQ ID NO:3). [Figure 6] FIG. 1 provides a table of Nic1 ERFs. [Figure 7]FIG. 1 provides a table of Nic2 ERFs. [Figure 8] ~ [Figure 15] FIG. 1 shows the sequences of ERF199 (SEQ ID NOs: 7 to 10) and ERF189 (SEQ ID NOs: 11 to 14). [Figure 16-1] ~ [Figure 16-5] FIG. 1 shows the sequence of TRV1 used in Example 1 (SEQ ID NO: 15). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0049] Some sequences disclosed herein contain "X" or "N" in the nucleotide sequence. "X" or "N" can be any nucleotide, or a deletion or insertion of one or more nucleotides. For example, in some cases, a string of "X" or "N" is shown. The number of "X" or "N" does not necessarily correlate to the actual number of nucleotides at that position. There may be more or fewer nucleotides than are shown as "X" or "N" in the sequence.

[0050] The inventors have shown, for the first time, that by modulating the activity or expression of at least one galactose-1-phosphate uridyltransferase in a plant (e.g., a tobacco plant) or cell (e.g., a tobacco cell), it is possible to modulate the alkaloid and / or TSNA precursor content of the plant (or treated plant) or cell.

[0051] Galactose-1-phosphate uridyltransferase or GalT plays an important role in galactose metabolism. GalT catalyzes the transfer of a uridyl diphosphate group on galactose (or glucose) 1-phosphate. During the reaction, the uridyl moiety is linked to a histidine residue. In the Escherichia coli enzyme, two histidine residues separated by one proline residue have been shown to be essential for the enzyme activity. The closest homolog of Nitab4.5_0002825g0060.2 in Arabidopsis (At5g18200, 62% identity) catalyzes the conversion of ADP-glucose and inorganic phosphate (Pi) to glucose-1-phosphate and ADP. The role of GalT in regulating pyridine alkaloid content in tobacco was unknown until now.

[0052] The present invention provides a method for modulating (e.g., reducing) the alkaloid content of a plant or part thereof, comprising modifying the plant by modulating (e.g., reducing) the activity or expression of at least one galactose-1-phosphate uridyltransferase.

[0053] Also provided is a method for modulating (e.g., decreasing) the content of tobacco-specific nitrosamine (TSNA) precursors in a tobacco plant or plant part thereof, the method comprising modifying the plant by modulating (e.g., decreasing) the activity or expression of at least one galactose-1-phosphate uridyltransferase.

[0054] The at least one galactose-1-phosphate uridyl transferase may be selected from the amino acid sequence set forth in SEQ ID NO: 3, or a functional variant, functional fragment, or orthologue thereof, or a sequence having at least 80% identity to SEQ ID NO: 3, or a homologue of SEQ ID NO: 3; alternatively, the at least one galactose-1-phosphate uridyl transferase may be encoded by a sequence set forth in SEQ ID NO: 1 or 2, or a functional variant, functional fragment, or orthologue of SEQ ID NO: 1 or 2, or a nucleic acid sequence having at least 80% identity to SEQ ID NO: 1 or 2, or a homologue of SEQ ID NO: 1 or 2.

[0055] In one embodiment, at least two genes encoding galactose-1-phosphate uridyl transferase are modified, selected from the group of genes encoding a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 3, or a functional variant, functional fragment, or orthologue thereof, or a sequence having at least 80% identity to SEQ ID NO: 3, or a homologue of SEQ ID NO: 3, or genes encoding a galactose-1-phosphate uridyl transferase comprising the nucleotide sequence set forth in SEQ ID NO: 1 or 2, or a functional variant, functional fragment, or orthologue of SEQ ID NO: 1 or 2, or a nucleic acid sequence having at least 80% identity to SEQ ID NO: 1 or 2, or a homologue of SEQ ID NO: 1 or 2.

[0056] In one embodiment, at least three, such as at least four, such as at least five, such as at least six, such as at least seven, such as at least eight, such as at least nine, such as ten, galactose-1-phosphate uridyl transferases are modulated, the galactose-1-phosphate uridyl transferases comprising the amino acid sequence set forth in SEQ ID NO: 3, or a functional variant or functional fragment or orthologue thereof, or a sequence having at least 80% identity to SEQ ID NO: 3, or a homologue of SEQ ID NO: 3, or comprising the nucleotide sequence set forth in SEQ ID NO: 1 or 2, or a functional variant or functional fragment or orthologue of SEQ ID NO: 1 or 2, or a nucleic acid sequence having at least 80% identity to SEQ ID NO: 1 or 2, or a homologue of SEQ ID NO: 1 or 2.

[0057] In one aspect, at least one galactose-1-phosphate uridyl transferase comprises or consists of the amino acid sequence set forth in SEQ ID NO: 3, or a functional variant, functional fragment, or ortholog thereof, or a sequence having at least 80% identity to SEQ ID NO: 3, or the galactose-1-phosphate uridyl transferase comprises the nucleotide sequence set forth in SEQ ID NO: 1 or 2, or a functional variant, functional fragment, or ortholog of SEQ ID NO: 1 or 2, or a nucleic acid sequence having at least 80% identity to SEQ ID NO: 1 or 2.

[0058] In one aspect, the activity or expression of at least one further gene is modulated. Suitably, at least two (or at least three or at least four or at least five or at least six or at least seven or at least eight or at least nine) additional genes selected from Table 1, or sequences with at least 80% sequence identity thereto, may also be modulated.

[0059] "Expression" of galactose-1-phosphate uridyltransferase may refer to the levels of transcription, translation, i.e., protein expression.

[0060] Measuring the level or amount of the gene product can be performed by any suitable method, for example by comparison of mRNA transcript levels, protein or peptide levels and / or plant phenotype between a modified plant and a comparable plant that has not been modified according to the invention.

[0061] The term "comparable product" as defined herein will be derived from a plant (e.g. tobacco plant) that has not been modified according to the present invention, but in which all other relevant characteristics (e.g. plant species, growth conditions, method of processing the plant, e.g. tobacco, etc.) are identical. A comparable product according to the present invention may mean, for example, a plant (e.g. tobacco plant) or a part thereof, such as leaves (e.g. tobacco leaves), harvested leaves (e.g. tobacco harvested leaves), cut harvested leaves (e.g. cut tobacco harvested leaves), processed leaves (e.g. tobacco processed leaves) or plant propagation material (e.g. tobacco plant propagation material) that can be obtained or obtained from a plant that has not been modified according to the present invention to modulate the activity or expression of a gene encoding galactose-1-phosphate uridyltransferase, or a product comprising said plant or a part therefore, such as a tobacco industry product or a combination thereof. In one embodiment, a comparable product is one that does not contain a gene encoding galactose-1-phosphate uridyltransferase, the activity or expression of which is modulated.

[0062] The term "modify" or "modified" as used herein refers to a plant (e.g., a tobacco plant) or a nucleic acid sequence that has been altered or changed. The present invention includes the modification of plants using techniques for the genetic modification of plants or non-genetic modification of plants. Such methods are well known in the art, and examples of genetic modification techniques include transformation, transgenic, cisgenic, and gene editing methods. Examples of non-genetic modification techniques include rapid neutron mutagenesis, chemical mutagenesis, e.g., ethyl methanesulfonate (EMS) mutagenesis, and modern population analysis approaches.

[0063] In one embodiment, natural variants with an engineered gene encoding galactose-1-phosphate uridyl transferase are selected and the trait or gene is bred into a second plant that may have a commercially desirable trait.

[0064] In one embodiment, the plant according to the invention is a transgenic plant. In one embodiment, the plant according to the invention is a non-transgenic plant.

[0065] The term "unmodified plant" as defined herein refers to a plant (e.g., tobacco plant) that has not been modified according to the present invention, for example, to regulate the activity or expression of galactose-1-phosphate uridyl transferase or to modify the nucleic acid sequence of at least one gene encoding galactose-1-phosphate uridyl transferase, and all other relevant characteristics (e.g., plant species, growing conditions, method of processing tobacco, etc.) are the same. In one embodiment, an unmodified plant is one that does not contain a gene encoding galactose-1-phosphate uridyl transferase whose activity or expression is modulated. In one embodiment, an unmodified plant is one that does not contain a modified nucleic acid sequence encoding at least one gene encoding galactose-1-phosphate uridyl transferase.

[0066] Galactose-1-phosphate uridyltransferase "Galactose-1-phosphate uridyltransferase," as used herein, refers to a catalytic protein that promotes the simultaneous conversion of uridine diphosphoglucose (UDP-glucose) and galactose-1-phosphate (gal-1P) to uridine diphosphogalactose (UDP-galactose) and glucose-1-phosphate.

[0067] Suitably, galactose-1-phosphate uridyl transferases can be identified using the assay described herein in Example 2. For example, galactose-1-phosphate uridyl transferases can be identified using the assay described in Mayes, JS and Hanson RG (1966) Methods in Enzymology IX, 708-713.

[0068] An exemplary sequence of a galactose-1-phosphate uridyltransferase from tobacco is shown in SEQ ID NO:3.

[0069] Galactose-1-phosphate uridyl transferases can be identified by comparing the amino acid sequence of the protein of interest with the amino acid sequence of SEQ ID NO:3.

[0070] In one aspect, the galactose-1-phosphate uridyl transferase according to the invention comprises or consists of the amino acid sequence set forth in SEQ ID NO: 3 or a sequence having at least 80% identity thereto, or a functional fragment thereof having galactose-1-phosphate uridyl transferase activity.

[0071] Domains within the amino acid sequence of a protein can be identified using domain prediction software known in the art. Domains are also described in protein databases, such as UniprotKB.

[0072] Without wishing to be bound by theory, it is hypothesized that modulating the content of galactose-1-phosphate uridyltransferase in plant cells or modulating the activity of galactose-1-phosphate uridyltransferase in plants will alter the metabolic pathways that produce alkaloids and TSNA precursors, resulting in modulated alkaloid and / or TSNA precursor content.

[0073] In one embodiment the galactose-1-phosphate uridyl transferase comprises the amino acid sequence shown as SEQ ID NO: 3 or a sequence having at least 80% identity thereto or a homologue thereof. Suitably, the homologue of SEQ ID NO: 3 may be selected from the group comprising the amino acid sequences provided in Table 1 or a sequence having at least 80% identity thereto.

[0074] In one embodiment, the galactose-1-phosphate uridyl transferase comprises an amino acid sequence set forth as SEQ ID NO: 3, or a sequence having at least 80% identity thereto (preferably, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto). In one embodiment, the galactose-1-phosphate uridyl transferase comprises an amino acid sequence set forth in Table 1, or a sequence having at least 80% identity thereto (preferably, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto).

[0075] In one embodiment, a galactose-1-phosphate uridyl transferase according to the invention comprises or consists of the amino acids set forth as SEQ ID NO: 3. In one embodiment, a galactose-1-phosphate uridyl transferase according to the invention comprises or consists of the amino acids set forth in Table 1.

[0076] Suitably the protein may be derived from Nicotiana tabacum.

[0077] In one embodiment, the galactose-1-phosphate uridyl transferase is encoded by a polynucleotide sequence, the gene (before mutation) comprising the polynucleotide sequence shown as SEQ ID NO: 1, or a sequence having at least 80% identity thereto, or a homologue thereof. Suitably, the homologue of SEQ ID NO: 1 may be selected from the group comprising the polynucleotide sequences provided in Table 1, or a sequence having at least 80% identity thereto.

[0078] In one embodiment, the galactose-1-phosphate uridyl transferase is encoded by a polynucleotide sequence set forth as SEQ ID NO: 1, or a sequence having at least 80% identity thereto (preferably, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto). In one embodiment, the galactose-1-phosphate uridyl transferase is encoded by a polynucleotide sequence set forth in Table 1, or a sequence having at least 80% identity thereto (preferably, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto).

[0079] In one embodiment, the galactose-1-phosphate uridyl transferase is encoded by a polynucleotide sequence that comprises, or consists of, the polynucleotide sequence set forth as SEQ ID NO: 1. In one embodiment, the galactose-1-phosphate uridyl transferase is encoded by a polynucleotide sequence that comprises, or consists of, the polynucleotide sequence set forth in Table 1.

[0080] In one embodiment, the galactose-1-phosphate uridyl transferase is encoded by a polynucleotide sequence, the gene (before mutation) comprising the polynucleotide sequence shown as SEQ ID NO: 2, or a sequence having at least 80% identity thereto, or a homologue thereof. Suitably, the homologue of SEQ ID NO: 2 may be selected from the group comprising the polynucleotide sequences provided in Table 1, or a sequence having at least 80% identity thereto.

[0081] In one embodiment, the galactose-1-phosphate uridyl transferase is encoded by a polynucleotide sequence set forth as SEQ ID NO:2, or a sequence having at least 80% identity thereto (preferably, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto). In one embodiment, the galactose-1-phosphate uridyl transferase is encoded by a polynucleotide sequence set forth in Table 1, or a sequence having at least 80% identity thereto (preferably, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto).

[0082] In one embodiment, the galactose-1-phosphate uridyl transferase is encoded by a polynucleotide sequence that comprises, or consists of, the polynucleotide sequence set forth as SEQ ID NO: 2. In one embodiment, the galactose-1-phosphate uridyl transferase is encoded by a polynucleotide sequence that comprises, or consists of, the polynucleotide sequence set forth in Table 1.

[0083] [Table 1] JPEG2025515313000002.jpg248170

[0084] Suitably, proteins for use according to the present invention may be encoded by polynucleotide sequences derived from Nicotiana tabacum.

[0085] In one aspect, the invention provides a method for reducing the alkaloid content of a plant or part or cell (e.g., a plant cell), comprising modifying the plant by reducing or inhibiting the activity or expression of at least one galactose-1-phosphate uridyltransferase.

[0086] In one aspect, the invention provides a method of reducing the alkaloid content of a plant or part thereof or a plant cell, the method comprising modifying the plant by reducing or inhibiting the activity or expression of at least one galactose-1-phosphate uridyl transferase, wherein the at least one galactose-1-phosphate uridyl transferase comprises the amino acid sequence set forth as SEQ ID NO:3, or a sequence with at least 80% identity thereto, or wherein at least one gene encoding a galactose-1-phosphate uridyl transferase comprises the nucleotide sequence set forth in SEQ ID NO:1 or 2, or a functional variant, functional fragment, or orthologue of SEQ ID NO:1 or 2, or a nucleic acid sequence with at least 80% identity thereto.

[0087] In one aspect, the present invention provides a method for reducing the content of tobacco specific nitrosamine (TSNA) precursors in a plant or part thereof (e.g., a leaf), comprising modifying said plant by reducing or inhibiting the activity or expression of at least one galactose-1-phosphate uridyl transferase. Suitably, the method comprises modifying said plant by reducing or inhibiting the activity or expression of at least one galactose-1-phosphate uridyl transferase, wherein said at least one galactose-1-phosphate uridyl transferase comprises the amino acid sequence set forth as SEQ ID NO:3, or a sequence having at least 80% identity thereto, or wherein at least one gene encoding a galactose-1-phosphate uridyl transferase comprises the nucleotide sequence set forth as SEQ ID NO:1 or 2, or a functional variant or functional fragment or orthologue of SEQ ID NO:1 or 2, or a nucleic acid sequence having at least 80% identity thereto.

[0088] In one aspect, the present invention provides a method for reducing the content of tobacco-specific nitrosamine (TSNA) precursors in a plant or part thereof (e.g., a leaf), comprising modifying the plant by reducing or inhibiting the activity or expression of at least one galactose-1-phosphate uridyltransferase.

[0089] In one aspect, the present invention provides a method for reducing the content of TSNAs in treated leaves, e.g., dried leaves, comprising: modifying the plant by reducing or inhibiting the activity or expression of at least one galactose-1-phosphate uridyltransferase; harvesting leaves from said plant; and processing, e.g., drying, the harvested leaves. The present invention provides a method comprising:

[0090] Suitably, the method of reducing the content of TSNAs in treated leaves may comprise modifying the plant by reducing or inhibiting the activity or expression of at least one galactose-1-phosphate uridyl transferase, wherein the at least one galactose-1-phosphate uridyl transferase comprises the amino acid sequence set forth as SEQ ID NO: 3, or a sequence having at least 80% identity thereto, or wherein at least one gene encoding a galactose-1-phosphate uridyl transferase comprises the nucleotide sequence set forth in SEQ ID NO: 1 or 2, or a functional variant or functional fragment or orthologue of SEQ ID NO: 1 or 2, or a nucleic acid sequence having at least 80% identity thereto. The terms "reducing" or "inhibiting" (e.g., inhibiting the activity or expression of galactose-1-phosphate uridyl transferase) as used herein means that the activity or expression of a gene encoding a galactose-1-phosphate uridyl transferase is lower or decreased compared to the activity or expression of the gene in a comparable product.

[0091] In one aspect, the invention provides a method for increasing the alkaloid content of a plant or part or cell (e.g., a plant cell), comprising modifying the plant by increasing or enhancing the activity or expression of at least one gene encoding galactose-1-phosphate uridyltransferase.

[0092] In one aspect, the invention provides a method of increasing the alkaloid content of a plant or part thereof or a plant cell, the method comprising modifying the plant by increasing or enhancing the activity or expression of at least one galactose-1-phosphate uridyltransferase, the at least one galactose-1-phosphate uridyltransferase comprising the amino acid sequence set forth as SEQ ID NO: 3, or a sequence having at least 80% identity thereto, or at least one gene encoding a galactose-1-phosphate uridyltransferase comprises the nucleotide sequence set forth in SEQ ID NO: 1 or 2, or a functional variant or functional fragment or orthologue of SEQ ID NO: 1 or 2, or a nucleic acid sequence having at least 80% identity thereto. In one aspect, the invention provides a method of increasing the content of tobacco specific nitrosamine (TSNA) precursors in a plant or part thereof (e.g., a leaf), the method comprising modifying the plant by increasing or enhancing the activity or expression of at least one galactose-1-phosphate uridyltransferase.

[0093] In one aspect, the invention provides a method of increasing the content of tobacco specific nitrosamine (TSNA) precursors in a plant or part thereof (e.g., a leaf), the method comprising modifying the plant by increasing or enhancing the activity or expression of at least one galactose-1-phosphate uridyl transferase, wherein the at least one galactose-1-phosphate uridyl transferase comprises the amino acid sequence set forth as SEQ ID NO:3, or a sequence having at least 80% identity thereto, or wherein at least one gene encoding a galactose-1-phosphate uridyl transferase comprises the nucleotide sequence set forth in SEQ ID NO:1 or 2, or a functional variant, functional fragment, or ortholog of SEQ ID NO:1 or 2, or a nucleic acid sequence having at least 80% identity thereto.

[0094] The terms "increasing" or "enhancing" (e.g., increasing the activity or expression of at least one gene encoding galactose-1-phosphate uridyl transferase) as used herein mean that the activity or expression of a gene encoding galactose-1-phosphate uridyl transferase is higher or increased compared to the activity or expression of the gene in a comparable product.

[0095] According to the present invention, the activity or expression of galactose-1-phosphate uridyltransferase is regulated.

[0096] In one aspect, the invention provides a method of modulating (i.e., increasing or decreasing) the alkaloid content of a plant or part or cell (e.g., a plant cell), comprising modifying the plant by modulating (i.e., increasing or decreasing) the activity of at least one galactose-1-phosphate uridyltransferase.

[0097] The term "activity" refers to any functionality of galactose-1-phosphate uridyl transferase.

[0098] For example, the activity of galactose-1-phosphate uridyltransferase can refer to its ability to simultaneously catalyze the conversion of uridine diphosphoglucose (UDP-glucose) and galactose-1-phosphate (gal-1P) to uridine diphosphogalactose (UDP-galactose) and glucose-1-phosphate. Methods for measuring such activity are known in the art.

[0099] Modulating the activity of galactose-1-phosphate uridyl transferase can require increasing or decreasing the activity of galactose-1-phosphate uridyl transferase.

[0100] Increasing the activity of galactose-1-phosphate uridyltransferase refers to enhancing or improving the ability of galactose-1-phosphate uridyltransferase to perform a particular function compared to galactose-1-phosphate uridyltransferase in a plant that has not been modified according to the present invention.

[0101] Reducing the activity of galactose-1-phosphate uridyltransferase refers to reducing, inhibiting or destroying the ability of galactose-1-phosphate uridyltransferase to perform a particular function, as compared to galactose-1-phosphate uridyltransferase in a plant that has not been modified according to the present invention. The activity of galactose-1-phosphate uridyltransferase can be reduced to such an extent that the activity is prevented or eliminated.

[0102] In some embodiments, the activity of galactose-1-phosphate uridyltransferase may be modulated (i.e., increased or decreased) by at least about 10%, 20%, 30% or 40%, suitably at least about 50%, 60%, 70%, more suitably at least about 80%, 90%, 95% or 100%, compared to the activity of a gene encoding galactose-1-phosphate uridyltransferase in a plant (e.g., a tobacco plant) that has not been modified according to the present invention. Suitably, the activity may be decreased.

[0103] In some embodiments, the modulated galactose-1-phosphate uridyl transferase exhibits increased or decreased activity compared to the unmodified galactose-1-phosphate uridyl transferase. The modulated galactose-1-phosphate uridyl transferase may exhibit increased or decreased activity of at least about 1%, at least about 3%, at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% compared to the unmodified galactose-1-phosphate uridyl transferase.

[0104] Techniques for measuring protein activity are known in the art, for example, methods for measuring galactose-1-phosphate uridyl transferase activity are described in Mayes and Hanson, supra.

[0105] In one aspect, the invention provides a method for modulating (i.e., increasing or decreasing) the alkaloid content of a plant or part thereof or a cell (e.g., a plant cell), comprising modifying the plant by modulating (i.e., increasing or decreasing) expression of at least one galactose-1-phosphate uridyltransferase.

[0106] "Expression" of a gene refers to the extent to which the information encoded by the gene is converted into functionality. The level of expression of a gene can be equated to the amount of the gene's product present in a cell or organism. A modification that modulates (i.e., increases or decreases) the expression of a gene is one that increases the amount of that gene's product in a plant or cell compared to an unmodified plant or cell.

[0107] In some embodiments, expression of the galactose-1-phosphate uridyl transferase gene is modulated (i.e., increased or decreased) compared to expression of a gene encoding galactose-1-phosphate uridyl transferase in a plant (e.g., a tobacco plant) that has not been modified according to the present invention.

[0108] In some embodiments, expression of the galactose-1-phosphate uridyl transferase gene may be modulated (i.e., increased or decreased) by at least about 10%, 20%, 30% or 40%, suitably at least about 50%, 60%, 70%, more suitably at least about 80%, 90%, 95% or 100%, compared to expression of a gene encoding galactose-1-phosphate uridyl transferase in a plant (e.g., a tobacco plant) that has not been modified according to the present invention. Suitably, expression may be decreased.

[0109] In some embodiments, the regulated galactose-1-phosphate uridyl transferase exhibits increased or decreased expression compared to unmodified galactose-1-phosphate uridyl transferase. The regulated galactose-1-phosphate uridyl transferase may exhibit increased or decreased expression by at least about 1%, at least about 3%, at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80% or at least about 90% compared to unmodified galactose-1-phosphate uridyl transferase. Suitably, the expression may be decreased.

[0110] Typically, genes are transcribed into mRNA, which is translated into a protein, the final gene product. Proteins may be sequestered in cellular stores and / or degraded. Expression of genes may be regulated by modulating any or all of these steps. Thus, in some embodiments, the modification modulates (e.g., reduces) expression of at least one gene encoding galactose-1-phosphate uridyl transferase in one of the following ways: modulating (e.g., decreasing) transcription from at least one gene encoding galactose-1-phosphate uridyl transferase; modulating (e.g., decreasing) translation of mRNA from at least one gene encoding galactose-1-phosphate uridyl transferase; modulating (e.g., decreasing) the release of galactose-1-phosphate uridyl transferase from intracellular stores; Modulating (e.g., increasing) the rate of degradation of galactose-1-phosphate uridyltransferase, and / or Decreasing or increasing its activity, for example, introducing a mutation that alters the amino acid sequence of galactose-1-phosphate uridyltransferase so as to decrease galactose-1-phosphate uridyltransferase activity.

[0111] The expression of a particular gene encoding galactose-1-phosphate uridyl transferase can be measured by measuring the transcription and / or translation of the gene. Methods for measuring transcription are well known in the art and include Northern blot, RNA-Seq, in situ hybridization, DNA microarray and RT-PCR, among others. Alternatively, the expression of a gene can be measured indirectly by measuring the level of a gene product, e.g., a protein encoded by the gene. For example, the expression of galactose-1-phosphate uridyl transferase can be determined by measuring the presence of the protein using an antibody specific for galactose-1-phosphate uridyl transferase by Western blot.

[0112] Modifications The plant or cell can be modified in any way that modulates the activity or expression of at least one galactose-1-phosphate uridyltransferase. The types of modifications to plants and cells that modulate gene activity or expression and techniques for achieving these modifications are known in the art.

[0113] In some embodiments, the present invention provides a method for reducing the alkaloid content of a plant or part thereof or a cell (e.g., a plant cell), comprising modifying the plant by reducing or inhibiting the activity or expression of at least one galactose-1-phosphate uridyltransferase described herein.

[0114] In some embodiments, the present invention provides a method for reducing the content of tobacco specific nitrosamines (TSNAs) or precursors of TSNAs in a tobacco plant or part of the plant, comprising modifying the plant or cell culture by reducing the activity or expression of at least one galactose-1-phosphate uridyltransferase described herein.

[0115] Any method known in the art for reducing or inhibiting the activity or expression of a gene or protein can be used in the methods according to the present invention.

[0116] Suitably, the activity or expression of the gene encoding galactose-1-phosphate uridyl transferase may be reduced, partially inactivated, inhibited, eliminated, knocked out or lost such that the protein activity, expression or function of the gene encoding galactose-1-phosphate uridyl transferase is undetectable.

[0117] In one embodiment, at least one gene encoding galactose-1-phosphate uridyl transferase is knocked out, in other words, the gene encoding galactose-1-phosphate uridyl transferase is completely disabled.

[0118] As an example, the method comprises: providing a mutation in a nucleic acid sequence encoding a protein comprising the amino acid sequence shown as SEQ ID NO:3 or an amino acid sequence having at least 80% sequence identity thereto; providing a mutation in a regulatory region (e.g. a promoter or enhancer) which contributes to controlling the expression of a protein comprising the amino acid sequence shown as SEQ ID NO:3 or an amino acid sequence having at least 80% sequence identity thereto, providing an antisense RNA, siRNA or miRNA that reduces the level of a nucleic acid sequence encoding a protein comprising the amino acid sequence set forth as SEQ ID NO:3 or an amino acid sequence having at least 80% sequence identity thereto; may include.

[0119] Each of the above approaches results in a reduction or prevention of activity or expression of a protein, wherein the protein comprises the amino acid sequence set forth as SEQ ID NO:3 or an amino acid sequence having at least 80% sequence identity thereto, or wherein at least one gene encoding galactose-1-phosphate uridyl transferase comprises the nucleotide sequence set forth in SEQ ID NO:1 or 2, or a functional variant or functional fragment or ortholog of SEQ ID NO:1 or 2, or a nucleic acid sequence having at least 80% identity thereto.

[0120] As used herein, the term "mutation" encompasses natural genetic variants or engineered variants. In particular, the term "mutation" refers to a variation in a nucleotide sequence encoding an amino acid sequence or in an amino acid sequence compared to the sequence shown as SEQ ID NO: 3 or an amino acid sequence having at least 80% (preferably at least 85%, preferably at least 90%, preferably at least 93%, preferably at least 95%, preferably at least 98%, preferably at least 99%) sequence identity thereto.

[0121] In one embodiment, the mutation reduces the alkaloid content of the plant.In another embodiment, the mutation reduces the content of at least one TSNA precursor in the plant or its part or leaf, for example, harvested or treated leaf.In one embodiment, the mutation reduces the content of one or more TSNAs selected from NNN, NNK, NAT, NAB, preferably NNK and / or NNK content in treated leaf.Appropriately, TSNA content is reduced in relation to comparable products.

[0122] In one embodiment, a method according to the invention may comprise the step of providing a nucleic acid sequence to a plant or part thereof or a plant cell, said nucleic acid resulting in the reduction or elimination of the activity or expression of at least one galactose-1-phosphate uridyl transferase.

[0123] In one embodiment, the method according to the invention may comprise the step of providing a nucleic acid sequence to a plant or part thereof or a plant cell, said nucleic acid resulting in the modification of at least one galactose-1-phosphate uridyl transferase nucleic acid sequence.

[0124] Suitably, the nucleic acid sequence may be introduced into a plant or part thereof or cell. Suitably, an endogenous nucleic acid sequence in a plant or part thereof or cell may be modified (e.g., by gene editing) to encode a polypeptide according to the present invention. For example, an endogenous nucleotide sequence may be modified to reduce the activity or expression of at least one galactose-1-phosphate uridyl transferase.

[0125] In a preferred embodiment, each copy of a nucleic acid sequence encoding a protein present in a plant, comprising a sequence set forth as SEQ ID NO: 3 or a sequence having at least 80% sequence identity thereto, or wherein at least one gene encoding galactose-1-phosphate uridyl transferase comprises a nucleotide sequence set forth as SEQ ID NO: 1 or 2 or a functional variant or functional fragment or orthologue of SEQ ID NO: 1 or 2 or a nucleic acid sequence having at least 80% identity thereto, is modified, e.g., mutated, as defined herein (e.g., each genomic copy of the gene encoding said protein in the plant is mutated). For example, each copy of the gene in the allotetraploid genome of Nicotiana tabacum can be mutated.

[0126] In a preferred embodiment, some or all of the homologs of the galactose-1-phosphate uridyl transferase described herein are modified, e.g., inhibited or mutated. Suitably, some or all of the homologs listed in Table 1, or corresponding sequences having at least 80% sequence identity thereto, are modified, e.g., inhibited or mutated.

[0127] In some embodiments, the plant or plant cell according to the invention is homozygous. Suitably, the plant or plant cell may be homozygous for the modification, e.g., the disruption or mutation.

[0128] In some embodiments, the plant or plant cell according to the invention expresses only modified, e.g. mutated, nucleic acid encoding at least one galactose-1-phosphate uridyltransferase. In other words, in some embodiments, there is no endogenous (or endogenous and functional protein) in the plant according to the invention. In other words, if any endogenous protein is present, it is preferably in an inactive form.

[0129] In one embodiment, the method may comprise providing a mutation in a nucleic acid sequence set forth as SEQ ID NO:1 or 2, or a nucleic acid sequence having at least 80% identity thereto, or a homologue of SEQ ID NO:1 or SEQ ID NO:2.

[0130] The mutation may alter the plant genome such that a nucleic acid sequence encoding a protein comprising the amino acid sequence set forth as SEQ ID NO:3, or an amino acid sequence having at least 80% sequence identity thereto, or a homologue of SEQ ID NO:3, is deleted, in whole or in part, or otherwise modified to inhibit or eliminate activity of galactose-1-phosphate uridyl transferase. In some embodiments, the mutation does not alter the level or expression of the protein, but reduces, inhibits, or eliminates activity of galactose-1-phosphate uridyl transferase.

[0131] Suitably, the at least one mutation may be in a non-cytoplasmic domain, a cytoplasmic domain or a transmembrane domain of galactose-1-phosphate uridyl transferase.

[0132] The mutation may disrupt the nucleic acid sequence encoding a protein comprising the amino acid sequence shown as SEQ ID NO:3, or an amino acid sequence having at least 80% sequence identity thereto, or a homologue of SEQ ID NO:3.

[0133] The interruption may result in the nucleic acid sequence not being transcribed and / or translated.

[0134] A nucleic acid sequence may be disrupted, for example, by deleting or otherwise altering the ATG start codon of the nucleic acid sequence, such that translation of protein is reduced or prevented.

[0135] The nucleic acid sequence may contain one or more nucleotide changes that reduce or prevent expression of the protein or that affect protein trafficking. For example, protein expression can be reduced or prevented by introducing one or more pre-mature stop codons, frameshifts, splice mutations, or impermissible amino acid substitutions in the open reading frame.

[0136] A premature stop codon refers to a mutation that introduces a stop codon into an open reading frame, preventing translation of the entire amino acid sequence. A premature stop codon can be a TAG ("amber"), TAA ("ochre"), or TGA ("opal" or "umber") codon.

[0137] A frameshift mutation (also called a framing error or reading frameshift) is a mutation caused by the insertion or deletion (insertion or deletion) of several nucleotides in a nucleic acid sequence that is not divisible by three. Due to the triplet nature of gene expression by codons, the insertion or deletion can change the reading frame and result in a completely different translation from the original. Frameshift mutations often cause the reading of the mutated codon to code for a different amino acid. Frameshift mutations generally result in the introduction of a premature stop codon.

[0138] Splice variants insert, delete or change several nucleotides at designated sites where splicing occurs during processing of precursor messenger RNA into mature messenger RNA. Deletion of a splice site can result in one or more introns remaining in the mature mRNA, leading to the production of an abnormal protein.

[0139] An unaccepted amino acid substitution refers to a mutation that results in a non-synonymous amino acid substitution in a protein, which results in reduced or eliminated function of the protein.

[0140] Any method known in the art for providing mutations in a nucleic acid sequence can be used in the method according to the invention. For example, homologous recombination can be used, in which the relevant nucleic acid sequence is mutated and a vector is generated that is used to transform the plant or plant cell. Recombinant plants or plant cells expressing the mutated sequence can then be selected.

[0141] In one embodiment, the mutation introduces an amino acid substitution that is not tolerated in a protein comprising the amino acid sequence shown as SEQ ID NO:3, or a sequence having at least 80% sequence identity thereto, or a homologue of SEQ ID NO:3.

[0142] In some embodiments, the galactose-1-phosphate uridyl transferase can contain a mutation that reduces expression or activity of galactose-1-phosphate uridyl transferase.

[0143] The mutations may be deletions, splice variants, or codons that code for impermissible amino acid substitutions.

[0144] In one embodiment, the nucleic acid sequence encoding galactose-1-phosphate uridyl transferase may be deleted in whole or in part. The deletion may be continuous or may include multiple sections of the sequence. The deletion preferably removes a sufficient amount of nucleotide sequence such that the nucleic acid sequence no longer encodes a functional galactose-1-phosphate uridyl transferase. The deletion may be complete when 100% of the coding portion of the nucleic acid sequence is not present when compared to the corresponding genome of a comparable unmodified plant. The deletion may, for example, remove at least 50, 60, 70, 80 or 90% of the coding portion of the nucleic acid sequence. Suitably, at least a portion of the protein may be deleted. The deletion may, for example, remove at least 10, 20, 30, 40, 50, 60, 70, 80 or 90% of the coding portion of the protein.

[0145] The deletion may remove at least 10 amino acids (e.g., at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90 amino acids) from the galactose-1-phosphate uridyl transferase. Suitably, the deletion may remove at least 10 amino acids (e.g., at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90 amino acids) of the galactose-1-phosphate uridyl transferase, and the sequence of the galactose-1-phosphate uridyl transferase is aligned with SEQ ID NO:3. Suitably, the deletion may remove at least 10 amino acids (e.g. at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90 amino acids) from the galactose-1-phosphate uridyl transferase, and the galactose-1-phosphate uridyl transferase before the deletion comprises the amino acid sequence shown in SEQ ID NO: 3, or a sequence having at least 80% sequence identity thereto, or a homologue of SEQ ID NO: 3. Suitably, the galactose-1-phosphate uridyl transferase before the deletion comprises the amino acid sequence shown in SEQ ID NO: 3.

[0146] Suitably, the protein for use according to the invention may comprise a truncated galactose-1-phosphate uridyltransferase. Suitably, the truncated protein may be a truncated version of the amino acid sequence shown in SEQ ID NO: 3 or a sequence having at least 80% sequence identity thereto, or a homologue of SEQ ID NO: 3. Suitably, the truncated protein lacks at least 10 amino acids (e.g. at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90 amino acids, at least 100 amino acids, finally 110 amino acids) from galactose-1-phosphate uridyltransferase.

[0147] The deletion may remove at least a portion of the domain. The deletion may, for example, remove at least 10, 20, 30, 40, 50, 60, 70, 80 or 90% of the domain. Suitably, the deletion may remove at least 5 amino acids, at least 10 amino acids, at least 15, at least 20, at least 25, at least 30 amino acids, at least 40 amino acids, at least 50 amino acids, at least 60 amino acids, at least 70 amino acids, at least 80 amino acids of the domain. Suitably, the deletion may remove 5 amino acids, 10 amino acids, 15, 20 amino acids, 25 amino acids, 30 amino acids, 40 amino acids, 50 amino acids, 60 amino acids, 70 amino acids, 80 amino acids of the domain.

[0148] The deletion may remove at least a part of the domain. The deletion may, for example, remove at least one or at least two amino acids from the domain. Suitably, the domain may be deleted completely.

[0149] Methods for the deletion of nucleic acid sequences in plants are known in the art. For example, homologous recombination can be used, in which a vector is generated that lacks the relevant nucleic acid sequence(s) and is used to transform the plant or plant cell. Recombinant plants or plant cells that express the new portion of the sequence can then be selected.

[0150] Plant cells transformed with the vectors described herein can be grown and maintained according to well-known tissue culture methods, for example, by culturing the cells in an appropriate culture medium supplemented with necessary growth factors, e.g., amino acids, plant hormones, vitamins, etc.

[0151] Modifications of nucleic acid sequences can be carried out using targeted mutagenesis, also called targeted nucleotide exchange (TNE) or oligo-directed mutagenesis (ODM). Targeted mutagenesis methods include, but are not limited to, those employing zinc finger nucleases, TALENs (see WO 2011 / 072246 and WO 2010 / 079430), Cas9-like, Cas9 / crRNA / tracrRNA, Cas9 / gRNA or other CRISPR systems (see WO 2014 / 071006 and WO 2014 / 093622), meganucleases (see WO 2007 / 047859 and WO 2009 / 059195) or targeted mutagenesis methods employing mutagenic oligonucleotides possibly containing chemically modified nucleotides to enhance mutagenesis using sequence complementarity to genes in plant protoplasts (e.g., KeyBase® or TALENs).

[0152] Alternatively, a mutagenesis system such as TILLING (Targeting Induced Local Lesions IN Genomics; McCallum et al. (2000) Nat. Biotech. 18:455, and McCallum et al. (2000) Plant Physiol. 123, 439-442, both incorporated herein by reference) can be used to generate plant lines containing genes encoding proteins with mutations. TILLING uses traditional chemical mutagenesis (e.g., ethyl methanesulfonate (EMS) mutagenesis to generate random mutations) followed by high-throughput screening for mutations. In this way, plants, seeds, cells and tissues containing genes with desired mutations can be obtained.

[0153] Methods may include mutagenizing plant seeds (e.g., EMS mutagenesis), pooling plant individuals or DNA, PCR amplification of the region of interest, heteroduplex formation and high-throughput detection, identification of mutant plants, and sequencing of mutant PCR products. It is understood that other mutagenesis and selection methods can equally be used to generate such modified plants. For example, seeds can be irradiated or chemically treated and plants can be screened for modified phenotypes.

[0154] Rapid neutron deletion mutagenesis can be used in a reverse genetic context (i.e., using PCR) to identify plant lines that carry deletions in endogenous genes. See, for example, Ohshima et al. (1998) Virology 213:472-481; Okubara et al. (1994) Genetics 137:867-874; and Quesada et al. (2000) Genetics 154:421-4315, which are incorporated herein by reference.

[0155] In another approach, dominant mutants can be used to induce RNA silencing by gene inversion and recombination of duplicated loci. See, e.g., Kusaba et al. (2003) Plant Cell 15:1455-1467, incorporated herein by reference.

[0156] Modified plants can be distinguished from unmodified plants, i.e. wild-type plants, by molecular methods, for example, by the mutation(s) present in the DNA, and by modified phenotypic characteristics. Modified plants can be homozygous or heterozygous for the modification. Preferably, modified plants are homozygous for the modification.

[0157] In one embodiment, the method of reducing or preventing the activity or expression of a protein comprising the amino acid sequence set forth as SEQ ID NO:3, or an amino acid sequence having at least 80% sequence identity thereto, or a homolog of SEQ ID NO:3, does not include treating the plant with a chemical (e.g., an agricultural chemical).

[0158] Other methods of reducing or preventing expression will be apparent to those of skill in the art and include the use of virus-induced gene silencing (VIGs), microRNA silencing, RNAi, antisense, tDNA insertions or dominant negative constructs (or antimorph mutations).

[0159] In one embodiment, expression of a gene encoding a protein comprising galactose-1-phosphate uridyl transferase, e.g., the amino acid sequence set forth as SEQ ID NO:3, or an amino acid sequence having at least 80% sequence identity thereto, can be reduced or eliminated by virus-induced gene silencing.

[0160] In one embodiment, expression of a gene encoding a protein comprising galactose-1-phosphate uridyl transferase, e.g., the amino acid sequence set forth as SEQ ID NO:3, or an amino acid sequence having at least 80% sequence identity thereto, may be reduced or eliminated by a microRNA.

[0161] In one embodiment, expression of a gene encoding a protein comprising galactose-1-phosphate uridyl transferase, e.g., the amino acid sequence set forth as SEQ ID NO:3, or an amino acid sequence having at least 80% sequence identity thereto, can be reduced or eliminated by RNAi.

[0162] In one embodiment, expression of a gene encoding a protein comprising galactose-1-phosphate uridyl transferase, e.g., the amino acid sequence set forth as SEQ ID NO:3, or an amino acid sequence having at least 80% sequence identity thereto, can be reduced or eliminated by antisense suppression.

[0163] In one embodiment, expression of a gene encoding a protein comprising galactose-1-phosphate uridyl transferase, e.g., the amino acid sequence set forth as SEQ ID NO:3, or an amino acid sequence having at least 80% sequence identity thereto, can be reduced or eliminated by sense suppression.

[0164] In one embodiment, expression of a gene encoding a protein comprising galactose-1-phosphate uridyl transferase, e.g., the amino acid sequence set forth as SEQ ID NO:3, or an amino acid sequence having at least 80% sequence identity thereto, can be reduced or eliminated by tDNA insertion.

[0165] In one embodiment, expression of a gene encoding a protein comprising galactose-1-phosphate uridyl transferase, e.g., the amino acid sequence set forth as SEQ ID NO:3, or an amino acid sequence having at least 80% sequence identity thereto, may be reduced or eliminated by a dominant negative construct (or antimorph mutation).

[0166] In one embodiment, expression of a gene encoding a protein comprising galactose-1-phosphate uridyl transferase, e.g., the amino acid sequence set forth as SEQ ID NO:3, or an amino acid sequence having at least 80% sequence identity thereto, can be reduced or eliminated by a targeted mutagenesis-based system.

[0167] In one embodiment, expression of a gene encoding a protein comprising galactose-1-phosphate uridyl transferase, e.g., the amino acid sequence set forth as SEQ ID NO:3, or an amino acid sequence having at least 80% sequence identity thereto, can be reduced or eliminated by gene editing, e.g., a CRISPR-based system.

[0168] In one embodiment, expression of a gene encoding a protein comprising the amino acid sequence set forth as SEQ ID NO:3 or an amino acid sequence having at least 80% sequence identity thereto may be reduced or eliminated by zinc finger nucleases, TALENs, meganucleases, mutagenic oligonucleotides or TILLING.

[0169] In some embodiments, the present invention provides a method for increasing the alkaloid content of a plant or part thereof or a cell (e.g., a plant cell), comprising modifying the plant by increasing or enhancing the activity or expression of at least one galactose-1-phosphate uridyltransferase.

[0170] Any method known in the art for increasing or enhancing gene activity or expression can be used in the methods according to the present invention.

[0171] In some embodiments, the method may include overexpressing at least one gene encoding galactose-1-phosphate uridyl transferase. Suitably, the method may include expressing one or more additional copies of at least one gene encoding galactose-1-phosphate uridyl transferase in the plant or cell. Suitably, the method may include modifying an endogenous copy of at least one gene encoding galactose-1-phosphate uridyl transferase such that its expression is increased. The method may include mutating a coding sequence of at least one gene encoding galactose-1-phosphate uridyl transferase. The method may include mutating a regulatory sequence that regulates the expression of at least one gene encoding galactose-1-phosphate uridyl transferase.

[0172] Suitably, the method may comprise transforming a cell of a plant (e.g., a tobacco plant) with a genetic construct encoding at least one galactose-1-phosphate uridyl transferase comprising the amino acid sequence shown in SEQ ID NO: 3 or a functional variant or functional fragment or orthologue thereof or a sequence having at least 80% identity to SEQ ID NO: 3 or a homologue of SEQ ID NO: 3, or wherein at least one gene encoding a galactose-1-phosphate uridyl transferase comprises a nucleotide sequence shown in SEQ ID NO: 1 or 2 or a functional variant or functional fragment or orthologue of SEQ ID NO: 1 or 2 or a nucleic acid sequence having at least 80% identity to SEQ ID NO: 1 or 2 or a homologue of SEQ ID NO: 1 or 2, or wherein the nucleotide sequence encoding a protein capable of enhancing or enhancing at least one endogenous galactose-1-phosphate uridyl transferase is included. It will be appreciated that each of these options results in increased activity and expression of the polypeptide encoded by the at least one galactose-1-phosphate uridyl transferase. The method may comprise regenerating a plant from the transformed cell. There is provided the use of a genetic construct capable of increasing the activity and / or expression of a polypeptide encoded by at least one gene encoding galactose-1-phosphate uridyl transferase to increase the alkaloid content (e.g., nicotine content) in a plant or part thereof or cell transformed with the construct.

[0173] The genetic construct may encode a polypeptide comprising the amino acid sequence SEQ ID NO:3 or a functional variant or functional fragment or orthologue thereof or a sequence having at least 80% identity to SEQ ID NO:3, or may comprise the nucleotide sequence shown in SEQ ID NO:1 or 2 or a functional variant or functional fragment or orthologue of SEQ ID NO:1 or 2 or a nucleic acid sequence having at least 80% identity to SEQ ID NO:1 or 2.

[0174] In another embodiment, the present invention relates to a method for increasing the alkaloid content of a plant or part or cell thereof, comprising modifying said plant or cell by increasing the activity of at least one galactose-1-phosphate uridyltransferase.

[0175] In one embodiment, the activity of at least one gene encoding galactose-1-phosphate uridyl transferase may be increased by introducing (or providing) a mutation in at least one gene encoding galactose-1-phosphate uridyl transferase.

[0176] Suitably, the activity of at least one gene encoding galactose-1-phosphate uridyl transferase may be increased by introducing a mutation into at least one gene encoding galactose-1-phosphate uridyl transferase, which comprises the amino acid sequence shown in SEQ ID NO: 3, or a functional variant or functional fragment or orthologue thereof, or a sequence having at least 80% identity to SEQ ID NO: 3, or wherein at least one gene encoding galactose-1-phosphate uridyl transferase comprises the nucleotide sequence shown in SEQ ID NO: 1 or 2, or a functional variant or functional fragment or orthologue of SEQ ID NO: 1 or 2, or a nucleic acid sequence having at least 80% identity to SEQ ID NO: 1 or 2.

[0177] In some embodiments, the activity or expression of at least one galactose-1-phosphate uridyl transferase is increased, thereby providing: modulating (e.g., increasing) transcription from at least one gene encoding galactose-1-phosphate uridyl transferase; modulating (e.g., increasing) translation of mRNA from at least one gene encoding galactose-1-phosphate uridyl transferase; modulating (e.g., increasing) the release of galactose-1-phosphate uridyl transferase from intracellular stores, and / or Regulating (e.g., decreasing) the rate of degradation of galactose-1-phosphate uridyltransferase Modifications that increase the alkaloid content by one of the following:

[0178] Alkaloid Content In one embodiment, the present invention provides a method for modulating the alkaloid content of a plant (e.g., a tobacco plant) or part thereof, comprising modifying the plant by modulating the activity or expression of at least one galactose-1-phosphate uridyltransferase.

[0179] The term "modulate" is used herein to mean either to increase or to decrease.

[0180] The term "increasing the alkaloid content" is used herein to mean that the alkaloid content in a product of the invention (e.g., a plant, a part thereof (e.g., a leaf), a treated leaf, or a product made from the plant (e.g., a tobacco industry product)) is higher compared to a comparable product that has not been modified according to the invention.

[0181] The term "reducing the alkaloid content" is used herein to mean that the alkaloid content in a product of the invention (e.g., a plant, a part thereof (e.g., a leaf), a treated leaf, or a product made from the plant (e.g., a tobacco industry product)) is lower compared to a comparable product that has not been modified according to the invention.

[0182] In some embodiments, modulating alkaloid content refers to increasing the alkaloid content, where the activity or expression of at least one galactose-1-phosphate uridyl transferase is increased (or, for example, the protein is overexpressed).

[0183] In some embodiments, modulating alkaloid content refers to a decrease in alkaloid content, where the expression of at least one galactose-1-phosphate uridyl transferase is reduced, inhibited or eliminated.

[0184] In a further embodiment, the alkaloid content is measured from leaves. In one embodiment, the alkaloid content is measured from green leaves. In a further embodiment, the alkaloid content is measured from dried leaves, such as from air-cured, flue-cured, fire-cured or sun-cured leaves. In a further embodiment, the alkaloid content is measured from flue-cured leaves. In a further embodiment, the alkaloid content is measured from air-dried leaves.

[0185] The term "alkaloid content" is used herein to mean the concentration and / or total amount of the entire group of compounds classified as alkaloids or the concentration and / or total amount of one or more compounds classified as alkaloids. Alkaloids typically present in tobacco include nornicotine, PON, anatabine, anabasine, nicotine and myosmine. In some embodiments, the content of one or more alkaloids selected from nicotine, nornicotine, PON, anatabine, anabasine and myosmine is adjusted, for example, two or three or more alkaloids, for example, three or four or more alkaloids, for example, four or five or more alkaloids, for example, five or six or more alkaloids, for example, all six alkaloids. In some embodiments, the content of one or more alkaloids selected from nicotine, nornicotine, PON, anatabine, anabasine, and myosmine, such as two or more alkaloids, such as three or more alkaloids, such as four or more alkaloids, such as five or more alkaloids, such as all six alkaloids, is increased. In some embodiments, the content of one or more alkaloids selected from nicotine, nornicotine, PON, anatabine, anabasine, and myosmine, such as two or more alkaloids, such as three or more alkaloids, such as four or more alkaloids, such as five or more alkaloids, such as all six alkaloids, is decreased. In some embodiments, the total alkaloid content of the plant or cell is regulated. In some embodiments, the total alkaloid content is increased. In some embodiments, the total alkaloid content is increased.

[0186] Any method known in the art for determining the concentration and / or total alkaloid content can be used. One preferred method for analyzing the alkaloid content includes analysis by gas chromatography-flame ionization detection (GC-FID) or by liquid chromatography with tandem mass spectrometry (LC-MS / MS).

[0187] In one embodiment, there is provided a method for producing a plant (e.g., a tobacco plant) or part thereof, plant propagation material (e.g., a tobacco plant propagation material), cell (e.g., a tobacco cell), leaf (e.g., a tobacco leaf), harvested leaf (e.g., harvested tobacco leaf), cut harvested leaf (e.g., cut harvested tobacco leaf), processed leaf (e.g., processed tobacco leaf), cut and processed leaf (e.g., cut and processed tobacco leaf), a product comprising said plant or or part thereof (e.g., a tobacco industry product), or combinations thereof, obtainable or obtained by a plant of the invention having modulated alkaloid content, the method comprising the step of modifying said plant to modulate the activity or expression of galactose-1-phosphate uridyltransferase. The adjusted alkaloid content can be determined by comparing the alkaloid content in a plant (e.g., a tobacco plant) or part thereof, plant propagation material (e.g., tobacco plant propagation material), cells (e.g., tobacco cells), leaves (e.g., tobacco leaves), harvested leaves (e.g., harvested tobacco leaves), cut harvested leaves (e.g., cut harvested tobacco leaves), processed leaves (e.g., processed tobacco leaves), cut and processed leaves (e.g., processed cut tobacco leaves), a product comprising a plant of the invention or a part thereof, e.g., a tobacco industry product, or combinations thereof, to a comparable product.

[0188] Suitably, the alkaloid content can be adjusted in a plant, for example, a tobacco plant, for example, a modified tobacco plant. Suitably, the alkaloid content can be adjusted in a leaf (for example, a tobacco leaf, for example, a tobacco leaf from a modified tobacco plant). Suitably, the alkaloid content can be adjusted in a harvested leaf (for example, a tobacco harvested leaf from a modified tobacco plant). Suitably, the alkaloid content can be adjusted in a cut harvested leaf (for example, a cut tobacco harvested leaf from a modified tobacco plant). Suitably, the alkaloid content can be adjusted in a processed leaf (for example, a processed tobacco leaf, for example, a processed tobacco leaf from a modified tobacco plant). Suitably, the alkaloid content can be adjusted in a cut and processed leaf (for example, a cut and processed tobacco leaf, for example, a cut and processed tobacco leaf from a modified tobacco plant). Suitably, the alkaloid content can be adjusted in a cured leaf (for example, a cured tobacco leaf from a modified tobacco plant). Suitably, the alkaloid content may be modulated in an extract of green leaves (e.g. green tobacco leaves from modified tobacco plants). Suitably, the alkaloid content may be modulated in a product comprising the plant of the invention or a part thereof (e.g. a tobacco industry product, e.g. a tobacco industry product produced from a modified tobacco plant or a part thereof). Suitably, the alkaloid content may be modulated in any of the above products or combinations thereof. Suitably, said modulated alkaloid content may be an increased alkaloid content. Suitably, said modulated alkaloid content may be a decreased alkaloid content (e.g. a decreased nornicotine and / or PON content).

[0189] In one embodiment, the content of one or more alkaloids selected from nornicotine, PON, anatabine and anabasine is reduced. In one embodiment, the content of nornicotine is reduced. In one embodiment, the content of PON is reduced. In one embodiment, the content of anatabine is reduced. In one embodiment, the content of anabasine is reduced.

[0190] In one embodiment, the nicotine content of the modified plant (e.g., tobacco plant), plant propagation material (e.g., tobacco plant propagation material), leaf (e.g., tobacco leaf), harvested leaf (e.g., tobacco harvested leaf), cut harvested leaf (e.g., cut harvested tobacco leaf), processed leaf (e.g., processed tobacco leaf), cut processed leaf (e.g., cut processed tobacco leaf) or tobacco industry product from the modified tobacco plant is not substantially reduced. Suitably, the nicotine content is at least 85% (e.g., at least 90%, e.g., at least 95%, e.g., at least 98%, e.g., at least 99%) of the nicotine content of a comparable product.

[0191] In one embodiment, the alkaloid content of the plant (e.g., tobacco plant) or part thereof may be modulated at least 0.5, 1.5, 2, 3 or 4 fold, respectively, when compared to the alkaloid content of a plant (e.g., tobacco plant) or part thereof grown under similar growth conditions that has not been modified to modulate the activity or expression of at least one gene encoding galactose-1-phosphate uridyl transferase. Suitably, the alkaloid content may be modulated from about 0.5 to about 4 fold. Suitably, the alkaloid content may be modulated about 4 fold. Suitably, the modification may be an increase or decrease in the alkaloid content. Suitably, the modulation may be of one or more alkaloids selected from nicotine, nornicotine, PON, anatabine, anabasine and myosmine. Suitably, the modulation may be of one or more alkaloids selected from nicotine, nornicotine, PON, anatabine and anabasine. Suitably, the nornicotine content may be reduced. Suitably, the PON content may be reduced. Suitably the anatabine content may be reduced. Suitably the anabasine content may be reduced.

[0192] In one embodiment of the invention, the alkaloid content of a plant (e.g., a tobacco plant) or part thereof may be modulated by at least 1%, 2%, 5%, 8%, 10%, 12%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% compared to a plant (e.g., a tobacco plant) or part thereof that has not been modified according to the invention. In one embodiment, the alkaloid content may be modulated by at least 30% compared to an unmodified plant or part thereof. In one embodiment, the alkaloid content may be modulated by at least 40% compared to an unmodified plant or part thereof. In one embodiment, the alkaloid content may be modulated by at least 50% compared to an unmodified plant or part thereof. In one embodiment, the alkaloid content may be modulated by at least 60% compared to an unmodified plant or part thereof. The modulation may be an increase or decrease in alkaloid content compared to an unmodified plant (e.g., a tobacco plant) or part thereof.

[0193] Suitably, the adjustment may be the adjustment of total alkaloid content. Suitably, the adjustment may be of one or more alkaloids selected from nornicotine, nicotine, PON, anatabine, anabasine and myosmine. Suitably, the adjustment may be of one or more alkaloids selected from nicotine, nornicotine, PON, anatabine and anabasine. Suitably, the adjustment may be the adjustment of nornicotine content, e.g., a reduction in nornicotine content. Suitably, the adjustment may be the adjustment of anabasine content, e.g., a reduction in anabasine content. Suitably, the adjustment may be the adjustment of PON content, e.g., a reduction in PON content. Suitably, the adjustment may be the adjustment of anatabine content, e.g., a reduction in anatabine content.

[0194] Suitably, modulation may be of more than one alkaloid selected from nicotine, nornicotine, PON, anatabine, anabasine and myosmine, such as two or more alkaloids, such as three or four or more alkaloids, such as four or five or more alkaloids, such as five or six or more alkaloids, such as all six alkaloids.

[0195] In some embodiments, the alkaloid content of the plant may be adjusted to between about 5% and about 100%, between about 10% and about 90%, between about 20% and about 80%, between about 30% and about 70%, between about 40% and 60%, between about 40% and 50%, or between about 50% and 60%.

[0196] Tobacco specific nitrosamine (TSNA) content In one embodiment, the present invention provides a method for reducing the content of at least one tobacco-specific nitrosamine (TSNA) precursor in a plant (e.g., a tobacco plant) or part thereof, or in a tobacco cell. Suitably, the method may comprise modifying said plant by modulating the activity or expression of at least one galactose-1-phosphate uridyl transferase. In one embodiment, the present invention provides a method for producing treated leaves having reduced TSNA content (e.g., relative to a comparable product). The method for producing treated leaves having reduced TSNA content comprises: modifying the plant by reducing or inhibiting the activity or expression of at least one galactose-1-phosphate uridyltransferase; harvesting leaves from said plant; and processing, e.g., drying, the harvested leaves. may include.

[0197] TSNAs can be measured in processed tobacco, such as cured tobacco or reconstituted tobacco. In one embodiment, TSNA content is measured and / or altered (e.g., reduced) in a cured tobacco plant or part thereof (e.g., in cured tobacco leaves).

[0198] The term "tobacco-specific nitrosamine" or "TSNA" as used herein has its ordinary meaning in the art, i.e., a nitrosamine found only in tobacco industry products or other nicotine-containing products. Suitably, the at least one tobacco-specific nitrosamine may be N'-nitrosonornicotine (NNN), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), N'-nitrosoanatabine (NAT) or N-nitrosoanabasine (NAB).

[0199] The term "precursor thereof," when used in connection with at least one tobacco-specific nitrosamine, refers to one or more chemicals or compounds of the tobacco plant that result in the formation of the tobacco-specific nitrosamine or that are involved in the nitrosation reaction that leads to the production of the tobacco-specific nitrosamine.

[0200] In one embodiment, the TSNA may be one or more of the group selected from N'-nitrosonornicotine (NNN), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), N'-nitrosoanatabine (NAT) and N'-nitrosoanabasine (NAB). Suitably, the at least one tobacco-specific nitrosamine may be NNK or NNN. In one embodiment, the tobacco-specific nitrosamine is NNN. In another embodiment, the tobacco-specific nitrosamine is NNK.

[0201] In one embodiment, the precursor of the TSNA is one or more of the group selected from nornicotine, anabasine, anatabine, and an oxidized derivative of nicotine, such as pseudooxynicotine (PON).

[0202] In one embodiment, the TSNA is N'-nitrosonornicotine (NNN) and / or the precursor is nornicotine. In one embodiment, the content of NNN is reduced. In one embodiment, the content of nornicotine is reduced. In one embodiment, the content of NNN and nornicotine is reduced.

[0203] In one embodiment, the TSNA is 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and / or the precursor is PON. In one embodiment, the content of NNK is reduced. In one embodiment, the content of PON is reduced. In one embodiment, the content of NNK and PON is reduced.

[0204] In one embodiment, the TSNA is N'-nitrosoanatabine (NAT) and / or the precursor is anatabine. In one embodiment, the content of NAT is decreased. In one embodiment, the content of anatabine is decreased. In one embodiment, the content of NAT and anatabine is decreased.

[0205] In one embodiment, the TSNA is N'-nitrosoanabasine (NAB) and / or the precursor is anabasine.

[0206] In one embodiment, the content of NAB is decreased. In one embodiment, the content of nornicotine is decreased. In one embodiment, the content of NAB and anabasine is decreased.

[0207] Precursors of TSNAs (e.g., NNK, NNN, NAB and / or NAT) can be measured, for example, in green tobacco leaves prior to processing, for example, prior to curing. In one embodiment, precursors of TSNAs (e.g., NNK, NNN, NAB and / or NAT) are measured and / or altered (e.g., reduced) in green tobacco leaves, for example, prior to processing, for example, prior to curing.

[0208] In one embodiment, practicing the method and / or use of the present invention results in a reduction of at least one TSNA or a precursor thereof in a modified tobacco plant (or part thereof) when compared to a tobacco plant (or part thereof) that has not been modified according to the present invention.

[0209] The term "reducing at least one TSNA or precursor thereof" or "reducing at least one TSNA or precursor thereof" is used herein to mean that the concentration and / or total content of at least one TSNA or precursor thereof in a product, method or use of the invention is lower in relation to a comparable product, method or use. For example, a comparable tobacco industry product would be derived from a tobacco plant that has not been modified according to the invention but where all other relevant characteristics (e.g., plant species, growing conditions, method of processing the tobacco, etc.) are the same.

[0210] Any method known in the art for determining the concentration and / or level of at least one TSNA or its precursor can be used. In particular, such a method may include the addition of deuterium-labeled internal standards, aqueous extraction and filtration, followed by analysis using reversed-phase high performance liquid chromatography (LC-MS / MS) with the possibility of using tandem mass spectrometry. Other examples for determining the concentration and / or level of precursors of tobacco-specific nitrosamines include the CORESTA recommended method CRM-72: Determination of Tobacco Specific Nitrosamines in Tobacco and Tobacco Products by LC-MS / MS; the CRM developed in ISO / DIS 21766, or methods such as those detailed in Wagner et al. (2005) Analytical Chemistry 77(4), 1001-1006, all of which are incorporated herein by reference.

[0211] Suitably, the concentration and / or total content of at least one tobacco specific nitrosamine or precursor thereof can be reduced by carrying out the method and / or use of the present invention. Suitably, the concentration and / or level of at least one tobacco specific nitrosamine or precursor thereof can be reduced in a tobacco plant of the present invention (e.g. obtainable or obtained by the method and / or use of the present invention) when compared to the concentration and / or level of at least one tobacco specific nitrosamine or precursor thereof in a tobacco plant that has not been modified according to the present invention.

[0212] The concentration and / or total content of at least one tobacco-specific nitrosamine or a precursor thereof in tobacco leaves, harvested leaves, processed tobacco leaves, tobacco industry products, or combinations thereof obtainable or derived from a tobacco plant (or part of a tobacco plant or tobacco cell culture) of the present invention can be reduced when compared to tobacco leaves, harvested leaves, processed tobacco leaves, tobacco industry products, or combinations thereof obtainable or derived from a tobacco plant (or part of a tobacco plant or tobacco cell culture) that has not been modified according to the present invention.

[0213] Suitably, the concentration and / or total content of at least one tobacco-specific nitrosamine or precursor thereof may be reduced in the treated tobacco leaves.

[0214] Suitably, the concentration and / or level of at least one tobacco-specific nitrosamine or precursor thereof in a tobacco industry product may be reduced.

[0215] In one embodiment, at least one tobacco-specific nitrosamine or precursor thereof can be reduced by at least about 1%, at least about 3%, at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, or at least about 50%. In some embodiments, at least one tobacco-specific nitrosamine or precursor thereof can be reduced by between about 5% and about 50%, between about 10% and about 50%, between about 20% and about 50%, between about 30% and about 50%, or between about 40% and 50%.

[0216] In the context of treated (e.g., cured) tobacco leaves (e.g., cured or reconstituted), at least one tobacco-specific nitrosamine or precursor thereof can be reduced by between about 5000 ng / g and about 50 ng / g, between about 4000 ng / g and about 100 ng / g, between about 3000 ng / g and 500 ng / g, or between 2000 ng / g and 1000 ng / g. In some embodiments, at least one tobacco-specific nitrosamine or precursor thereof can be reduced by at least about 5000 ng / g, at least about 4000 ng / g, at least about 3000 ng / g, at least about 2000 ng / g, at least about 1000 ng / g, at least about 500 ng / g, at least about 100 ng / g, or at least about 50 ng / g.

[0217] Biomass Generation In some cases, it may be desirable to produce plants or biomass with high alkaloid levels, e.g., high levels of nicotine content, so that the nicotine can be purified to produce pure nicotine products, e.g., for use in devices that utilize nicotine-containing liquids (e.g., e-cigarettes) or in tobacco heating devices. For example, producing nicotine in this manner could reduce the cost of nicotine extraction for the production of e-liquids for e-cigarettes.

[0218] In one aspect, the present invention provides a method for producing biomass, comprising the steps of: Growing the cells that have been engineered to modulate (e.g., increase) the activity or expression of a gene encoding galactose-1-phosphate uridyl transferase under conditions that produce biomass. Suitably, the activity or expression of galactose-1-phosphate uridyl transferase can be increased to increase the concentration and / or total nicotine content.

[0219] In one embodiment, the invention provides a method of producing biomass with an altered (e.g., increased) concentration and / or total nicotine content, comprising growing a cell that has been engineered to increase activity or expression of at least one galactose-1-phosphate uridyl transferase comprising the amino acid sequence set forth in SEQ ID NO:3, or a functional variant or functional fragment or orthologue thereof, or a sequence having at least 80% identity to SEQ ID NO:3, or a homologue of SEQ ID NO:3; or wherein the at least one galactose-1-phosphate uridyl transferase comprises the nucleotide sequence set forth in SEQ ID NO:1 or 2, or a functional variant or functional fragment or orthologue of SEQ ID NO:1 or 2, or a nucleic acid sequence having at least 80% identity to SEQ ID NO:1 or 2, or a homologue of SEQ ID NO:1 or 2.

[0220] The cells can be engineered by any method known in the art to alter the activity or expression of at least one galactose-1-phosphate uridyl transferase. Suitably, the cells can be engineered to express an exogenous gene encoding a galactose-1-phosphate uridyl transferase. Suitably, the cells can be engineered to overexpress a gene encoding a galactose-1-phosphate uridyl transferase.

[0221] Suitably, the biomass may contain a higher concentration and / or total content of nicotine compared to biomass produced by a comparable cell that has not been modified in accordance with the present invention.

[0222] Suitably, the cell for use in biomass production may be a plant cell, for example a tobacco cell.

[0223] Suitably, the cells for use in biomass production may be yeast cells.

[0224] In one embodiment, the cell (e.g., yeast cell) can be further modified to include one or more sequences that increase nicotinic alkaloid biosynthesis. Suitably, these one or more sequences can be incorporated into a nucleic acid construct that is suitable for cell (e.g., yeast cell) transformation. The one or more sequences can be overexpressed in the cell (e.g., yeast cell). The sequences can be selected from one or more of the following genes: : MPO (or methylputrescine oxidase or MPO1 or MPO2), A622 (or isoflavone reductase-like protein or isoflavone reductase homolog or isoflavone reductase-like protein), BBL (or berberine bridge enzyme or berberine bridge enzyme-like or BBE or NBB1), PMT (or putrescine N-methyltransferase or putrescine methyltransferase or S-adenosyl-L-methionine:putrescine N-methyltransferase or PMT or PMT1 or PMT2 or PMT3 or PMT4) and QPT (or quinolinic acid phosphoribosyltransferase). In one embodiment, the sequence may be selected from one or more of the following genes: BBL, A622, PMT and MPO (MPO1 or MPO2). Suitable genes for modification in this manner may be taught, for example, in US2016032299, which is incorporated herein by reference.

[0225] Commercially desirable traits In one embodiment, the plant of the invention has an altered (e.g. increased or decreased) total alkaloid content and / or an altered (e.g. increased or decreased) content of one or more alkaloids, while at least the flavor characteristics and / or other commercially desirable traits are maintained. Suitably, the plant of the invention may have a reduced total alkaloid content and / or a reduced content of one or more alkaloids, while at least the flavor characteristics and / or other commercially desirable traits are maintained.

[0226] In one embodiment, a plant of the present invention produces leaves of a similar grade and / or quality as a plant that has not been modified according to the present invention.

[0227] In one embodiment, a plant of the present invention has reduced nornicotine and / or PON and / or anabasine and / or anatabine content without a significant change in the flavor profile of the plant (e.g., compared to the same plant not modified according to the present invention).

[0228] In one embodiment, a plant of the invention has reduced TSNA precursor content without significant alteration (e.g., reduction) of other commercially desirable traits of the plant (e.g., compared to the same plant not modified according to the invention). In particular, the yield of the modified plant is preferably not reduced compared to the same plant not modified according to the invention.

[0229] Thus, in one embodiment, the methods and uses of the present invention relate to reducing TSNA precursor content while maintaining flavor characteristics and / or other commercially desirable traits (eg, yield).

[0230] The term "commercially desirable trait", as used herein, includes traits such as yield, mature plant height, number of harvestable leaves, average node length, cutter leaf length, cutter leaf width, quality (e.g. leaf quality, suitably dry leaf quality), abiotic (e.g. drought) stress tolerance, herbicide tolerance and / or biotic (e.g. insect, bacterial or fungal) stress tolerance.

[0231] Leaf quality can be measured, for example, based on the color, texture and aroma of the dried leaves according to United States Department of Agriculture (USDA) grades and standards.

[0232] Tobacco grades are assessed based on factors including, but not limited to, petiole position, leaf size, leaf color, leaf uniformity and integrity, maturity, texture, elasticity, gloss (related to the intensity and depth of coloration and brilliance of the leaf), hygroscopicity (the ability of the tobacco leaf to absorb and retain environmental moisture) and green shade or appearance.

[0233] Leaf grades can be determined using standard methods known in the art, for example, using the official standard grades issued by the Agricultural Marketing Service of the United States Department of Agriculture (7 USC § 511). For example, official standard grades for burley tobacco (U.S. Type 31 and foreign Type 93), effective November 5, 1990 (55 FR 40645); official standard grades for flue-cured tobacco (U.S. Types 11, 12, 13, 14, and foreign Type 92), effective March 27, 1989 (54 FR 7925); official standard grades for Pennsylvania seed leaf tobacco (U.S. Type 41), effective January 8, 1965 (29 FR 16854); official standard grades for Ohio cigar leaf tobacco (U.S. Types 42, 43, and 44), effective December 8, 1963 (28 FR 11719 and 28 FR 11926); official standard grades for Wisconsin cigar binder tobacco (U.S. Types 54 and 55), effective November 20, 1969 (34 FR 12261); 17061); Official Standard Grades for Wisconsin Cigar Binder Tobacco (U.S. Types 54 and 55), effective November 20, 1969 (34 FR 17061); Official Standard Grades for Georgia and Florida Shade-Grown Cigar-Wrapper Tobacco (U.S. Type 62), effective April 1971. USDA grade index values ​​can be determined according to industry-recognized grade indexes. See, e.g., Bowman et al. (1988) Tobacco Science, 32:39-40; Legacy Tobacco Document Library (Bates Document #523267826-523267833, July 1, 1988, Memorandum on the Proposed Burley Tobacco Grade Index); and Miller et al. (1990) Tobacco Intern., 192:55-57 (all of the above references are incorporated herein in their entirety).

[0234] In one embodiment, the USDA grade index is a numerical representation of the received federal grade from 0 to 100, which is a weighted average of all petiole positions. A higher grade index indicates higher quality. Alternatively, leaf grade can be determined by hyperspectral imaging. See, for example, WO 2011 / 027315, which is incorporated herein by reference.

[0235] In one embodiment, the tobacco plants of the present invention provide tobacco of a commercially acceptable grade.

[0236] Suitably, the tobacco plants of the present invention provide cured tobacco of a commercially acceptable grade.

[0237] In one embodiment, a tobacco plant of the present invention is capable of producing a leaf having a USDA grade index value that is at least about 70% of the USDA grade index value of a leaf of a comparable plant when grown under similar growth conditions. Suitably, a tobacco plant disclosed herein may be capable of producing a leaf having a USDA grade index value that is at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 98% of the USDA grade index value of a control plant when grown under similar growth conditions. Suitably, the tobacco plants disclosed herein may be capable of producing leaves having a USDA grade index value of between 65% and 130%, between 70% and 130%, between 75% and 130%, between 80% and 130%, between 85% and 130%, between 90% and 130%, between 95% and 130%, between 100% and 130%, between 105% and 130%, between 110% and 130%, between 115% and 130%, or between 120% and 130% of the USDA grade index value of a comparable plant.

[0238] In one aspect, a tobacco plant of the present invention is capable of producing leaves having a USDA Grade Index value of at least 50. Suitably, the tobacco plants disclosed herein may be capable of producing leaves having a USDA Grade Index value of 55 or greater, 60 or greater, 65 or greater, 70 or greater, 75 or greater, 80 or greater, 85 or greater, 90 or greater, and 95 or greater.

[0239] Unless otherwise specified, as used herein, tobacco yield refers to cured leaf yield calculated based on the weight of cured tobacco leaf per acre under standard field conditions according to standard agricultural and curing practices.

[0240] In one embodiment, a plant (e.g., a tobacco plant) of the invention has a yield of between 50% and 150%, between 55% and 145%, between 60% and 140%, between 65% and 135%, between 70% and 130%, between 75% and 125%, between 80% and 120%, between 85% and 115%, between 90% and 110%, between 95% and 105%, between 50% and 100%, between 55% and 100%, between 60% and 100%, between 65% and 100%, or between 100% and 150% of the yield of a comparable plant grown under similar field conditions. %, between 70% and 100%, between 75% and 100%, between 80% and 100%, between 85% and 100%, between 90% and 100%, between 95% and 100%, between 100% and 150%, between 105% and 150%, between 110% and 150%, between 115% and 150%, between 120% and 150%, between 125% and 150%, between 130% and 150%, between 135% and 150%, between 140% and 150% or between 145% and 150%.

[0241] In another aspect, the yield of a plant of the invention (e.g., a tobacco plant) is approximately 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, or 3.0 times the yield of a comparable plant grown under similar field conditions.

[0242] In another aspect, the yield of the tobacco plants of the present invention is comparable to the yield of comparable flue-cured plants when grown under similar field conditions.

[0243] In one embodiment, the tobacco plants of the present invention provide a yield selected from the group consisting of about between 1200 and 3500 pounds / acre, between 1300 and 3400 pounds / acre, between 1400 and 3300 pounds / acre, between 1500 and 3200 pounds / acre, between 1600 and 3100 pounds / acre, between 1700 and 3000 pounds / acre, between 1800 and 2900 pounds / acre, between 1900 and 2800 pounds / acre, between 2000 and 2700 pounds / acre, between 2100 and 2600 pounds / acre, between 2200 and 2500 pounds / acre, and between 2300 and 2400 pounds / acre.

[0244] In another embodiment, the tobacco plants of the present invention produce between about 1200 and 3500 pounds / acre, between 1300 and 3500 pounds / acre, between 1400 and 3500 pounds / acre, between 1500 and 3500 pounds / acre, between 1600 and 3500 pounds / acre, between 1700 and 3500 pounds / acre, between 1800 and 3500 pounds / acre, between 1900 and 3500 pounds / acre, between 2000 and 3500 pounds / acre, between 2100 and 3500 pounds / acre, The present invention provides a yield selected from the group consisting of between 2200 and 3500 pounds / acre, between 2300 and 3500 pounds / acre, between 2400 and 3500 pounds / acre, between 2500 and 3500 pounds / acre, between 2600 and 3500 pounds / acre, between 2700 and 3500 pounds / acre, between 2800 and 3500 pounds / acre, between 2900 and 3500 pounds / acre, between 3000 and 3500 pounds / acre and between 3100 and 3500 pounds / acre.

[0245] In further embodiments, the tobacco plants of the present invention produce between about 1200 and 3500 pounds / acre, between 1200 and 3400 pounds / acre, between 1200 and 3300 pounds / acre, between 1200 and 3200 pounds / acre, between 1200 and 3100 pounds / acre, between 1200 and 3000 pounds / acre, between 1200 and 2900 pounds / acre, between 1200 and 2800 pounds / acre, between 1200 and 2700 pounds / acre, between 1200 and 2600 pounds / acre, between 1200 and 2500 pounds / acre. In one embodiment, the present invention provides a yield selected from the group consisting of between 1200 and 2400 lbs / acre, between 1200 and 2300 lbs / acre, between 1200 and 2200 lbs / acre, between 1200 and 2100 lbs / acre, between 1200 and 2000 lbs / acre, between 1200 and 1900 lbs / acre, between 1200 and 1800 lbs / acre, between 1200 and 1700 lbs / acre, between 1200 and 1600 lbs / acre, between 1200 and 1500 lbs / acre and between 1200 and 1400 lbs / acre.

[0246] plant breeding In one embodiment, the present invention provides a. crossing a donor plant having altered (e.g., reduced) nicotine content and / or altered (e.g., reduced) tobacco specific nitrosamine (TSNA) precursor content and wherein the activity or expression of at least one galactose-1-phosphate uridyltransferase according to the invention has been modulated (e.g., reduced) in the donor plant according to the invention with a recipient tobacco plant having an unaltered nicotine content or unaltered tobacco specific nitrosamine (TSNA) precursor content and commercially desirable traits; b. isolating genetic material from a progeny of the donor plant mated with the recipient plant; and c. performing molecular marker assisted selection using molecular markers, Identifying an introgression region containing a mutation in the polynucleotide sequence encoding the protein defined in ia. performing molecular marker assisted selection, The present invention provides a method for producing a plant having altered alkaloid content and / or altered tobacco specific nitrosamine (TSNA) precursor content, comprising:

[0247] Suitably, the activity or expression of a protein comprising the amino acid sequence as set forth in SEQ ID NO: 3, or a functional variant or functional fragment or orthologue thereof, or a sequence having at least 80% identity to SEQ ID NO: 3, or a homologue of SEQ ID NO: 3, or a nucleotide sequence as set forth in SEQ ID NO: 1 or 2, or a functional variant or functional fragment or orthologue of SEQ ID NO: 1 or 2, or a nucleic acid sequence having at least 80% identity to SEQ ID NO: 1 or 2, or a homologue of SEQ ID NO: 1 or 2, is modulated in the donor plant when compared to an equivalent plant. Suitably, the method reduces the alkaloid content and / or TSNA precursor content. Suitably, the alkaloid content and / or TSNA precursor content is reduced and the activity or expression of said galactose-1-phosphate uridyltransferase is reduced or inhibited.

[0248] Molecular marker assisted selection may involve performing PCR to identify introgressed nucleic acid sequences that contain mutations that modulate the activity or expression of a protein comprising the amino acid sequence set forth in SEQ ID NO:3, or an amino acid sequence having at least 80% identity thereto.

[0249] Tobacco plant The present invention provides methods, uses directed to plants (eg, tobacco plants), as well as cells (eg, tobacco cells), cell cultures, plants (eg, tobacco plants), and plant propagation material.

[0250] The term "tobacco plant" as used herein refers to a plant of the genus Nicotiana used in the manufacture of tobacco industry products. Non-limiting examples of suitable "tobacco" plants include N. tabacum and N. rustica (e.g., N. tabacum L., LA B21, LN KY171, TI 1406, Basma, Galpao, Perique, Beinhart 1000-1, and Petico).

[0251] The tobacco material may be derived or obtained from various Nicotiana tabacum types, commonly known as burley, flue or bright, and dark. In some embodiments, the tobacco material is derived from a burley, Virginia, or dark tobacco plant. The tobacco plant may be selected from burley tobacco, rare tobacco, specialty tobacco, expanded tobacco, or the like.

[0252] The use of tobacco cultivars and elite tobacco cultivars is also contemplated herein. The tobacco plants for use herein may therefore be of Nicotiana species or elite tobacco cultivars. Particularly useful Nicotiana tabacum species include flue-cured Virginia type, Burley type, and Oriental type.

[0253] One of the snowflakes is the 1st of the 2nd Material No.: L. No. Ti1068 AA37-1.B 13P Xanthi(Mitchell-Mor) KT D#3 107 Bel-W3 79-615 Samsun Holmes NN BU21×Sheet Parado's license plate is F4, number 97, KTRDC#2 page 49, KTRDC#4 page 1 10, バーレー21, PM016, KTRDC#5 KY 160 SI, KTRDC#7 FCA, KTRDC#6 TN 86 SI, PM021, K 149, K 326, K 346, K 358, K 394, K 399, K 730, KY 10, KY 14, KY 160, KY 17, KY 8959, KY 9, KY 907, MD 609, McNair 373, NC 2000, PG 01, PG 04, P01, P02, P03, RG 11, RG 17, RG 8, Speight G-28, TN 86, TN 90, VA 509, AS44, Banquet A1, Basma Drama B84 / 31, Basma I Study ZP4 / B, Basma Xanthi BX 2A, Batek, Besuki Jember, C104, Coker 319, Coker 347, Creole Missionary, PM092, Delcrest, Djebel 81, DVH 405, Galpao Comum, HB04P, Hicks Broadleaf, Kabakulak Elassona, PM102, Kutsage E1, KY 14×L8, KY 171, LA BU 21, McNair 944, NC 2326, NC 71, NC 297, NC 3, PVH 03, PVH 09, PVH 19, PVH 21 10, Red Russian, Samsun, Saplak, Simmaba, Talgar 28, PM132, Wislica, Yayaldag, NC 4, TR Madole, Prilep HC-72、Prilep P23、Prilep PB 156 / 1、Prilep P12-2 / 1、About JK-48、About JB125 / 3, ΤΙ-1068, KDH-960, TI-1070, TW136, PM204, PM205, Basma, TKF 4028, L8, TKF 2002, TN 90, GR141, Basma xanthi, GR149, GR153, and Petit Havana.

[0254] Non-limiting examples of species or cultivars are: BD 64, CC 101, CC 200, CC 27, CC 301, CC 400, CC 500, CC 600, CC 700, CC 800, CC 900, Coker 176, Coker 319, Coker 371 Gold, Coker 48, CD 263, DF91 1, DT 538 LC, Galpao tobacco, GL 26H, GL 350, GL 600, GL 737, GL 939, GL 973, HB 04P, HB 04P LC, HB3307PLC, Hybrid 403LC, Hybrid 404LC, Hybrid 501 LC, K 149, K 326, K 346, K 358, K394, K 399, K 730, KDH 959, KT 200, KT204LC, KY10, KY14, KY 160, KY 17, KY 171, KY 907, KY907LC, KTY14xL8 LC, Little Crittenden, McNair 373, McNair 944, msKY 14xL8, Narrow Leaf Madole, Narrow Leaf Madole LC, NBH 98, N-126, N-777LC, N-7371 LC, NC 100, NC 102, NC 2000, NC 291, NC 297, NC 299, NC 3, NC 4, NC 5, NC 6, NC7, NC 606, NC 71, NC 72, NC 810, NC BH 129, N.C. 2002, Neal Smith Madole, OXFORD 207, PD 7302 LC, PD 7309 LC, PD 7312 LC "Periq'e" Tobacco, PVH03, PVH09, PVH19, PVH50, PVH51, R 610, R 630, R 7-1 1, R 7-12, RG 17, RG 81, RG H51, RGH 4, RGH 51, RS 1410, Speight 168, Speight 172, Speight 179, Speight 210, Speight 220, Speight 225, Speight 227, Speight 234, Speight G-28, Speight G-70, Speight H-6, Speight H20, Speight NF3, Tl 1406, Tl 1269, TN86, TN86LC, TN 90, TN 97, TN97LC, TN D94, TN D950, TR (Tom Rosson) Madole, VA 309, VA359, AA 37-1, B 13P, Xanthi (Mitchell-Mor), Bel-W3, 79-615, Samsung Holmes NN, KTRDC number 2 hybrid 49, Burley 21, KY 8959, KY 9, MD 609, PG 01, PG 04, P01, P02, P03, RG 1 1, RG 8, VA 509, AS44, Banket A1, Basma Drama B84 / 31, Basma I Zichna ZP4 / B, Basma Xanthi BX 2A, Batek, Besuki Jember, C104, Coker 347, Criollo Misionero, Delcrest, Djebel 81, DVH 405, Galpao Comum, HB04P, Hicks Broadleaf, Kabakulak Elassona, Kutsage E1, LA BU 21, NC 2326, NC 297, PVH 21 10, Red Russian, Samsun, Saplak, Simmaba, Talgar 28, Wislica, Yayaldag, Prilep HC-72, Prilep P23, Prilep PB 156 / 1, Prilep P12-2 / 1, Yaka JK-48, Yaka JB 125 / 3, TI-1068, KDH-960, Tl-1070, TW136, Basma, TKF 4028, L8, TKF 2002, GR141, Basma xanthi, GR149, GR153, Petit Havana. Less converted variants of the above are also contemplated, even if not specifically identified herein.

[0255] The tobacco plant can be burley, flue-cured Virginia, or oriental.

[0256] In one embodiment, plant propagation material can be obtained from a plant of the invention (eg, a tobacco plant).

[0257] "Plant propagation material" as used herein refers to any plant matter obtained from a plant from which further plants may be generated. Suitably, the plant propagation material may be selected from seeds, plant callus, and plant mass. Suitably, the plant propagation material may be seeds. Suitably, the plant propagation material may be plant callus. Suitably, the plant propagation material may be plant mass.

[0258] In one embodiment, cells (eg, tobacco cells), cell cultures, tobacco plants, and / or plant propagation material are obtainable (eg, obtainable) by a method according to the invention.

[0259] Suitably, tobacco plants according to the present invention that have been modified to modulate (e.g., reduce) the activity or expression of at least one galactose-1-phosphate uridyl transferase may have a modulated (e.g., reduced) nicotine content when compared to an unmodified tobacco plant. Suitably, tobacco plants according to the present invention that have been modified to reduce or inhibit the activity or expression of at least one galactose-1-phosphate uridyl transferase may have a reduced nicotine content when compared to an unmodified tobacco plant.

[0260] Suitably, tobacco plants according to the present invention may have a modulated (e.g. reduced) content of tobacco specific nitrosamine (TSNA) precursors when compared to an unmodified tobacco plant, where the tobacco plant has been modified to modulate (e.g. decrease) the activity or expression of at least one galactose-1-phosphate uridyltransferase.

[0261] Suitably, tobacco plants according to the present invention that have been modified to reduce or inhibit the activity or expression of at least one galactose-1-phosphate uridyltransferase may have a reduced tobacco-specific nitrosamine (TSNA) precursor content when compared to an unmodified tobacco plant.

[0262] In one embodiment, a tobacco plant according to the invention comprises a tobacco cell of the invention.

[0263] In another embodiment, plant propagation material can be obtained (eg, obtained) from a tobacco plant of the present invention.

[0264] In one embodiment, there is provided a use of a tobacco plant as described herein for breeding tobacco plants.

[0265] The present invention also provides, in another embodiment, the use of the tobacco plant of the previous embodiment for producing a tobacco industry product.

[0266] In another embodiment, there is provided a use of a tobacco plant of the present invention to produce a crop.

[0267] In one embodiment, there is provided a use of a cell as provided in the previous embodiment for producing a tobacco industry product.

[0268] In one embodiment, the invention provides a cell culture (eg, an in vitro culture).

[0269] The tobacco cell culture may be a cell suspension culture. These in vitro cultured cells may be incorporated into tobacco industry products, for example as a replacement for traditional tobacco particles, shreds, fine cut or long cut tobacco flakes, as an additive component, or both as a replacement and an additive. Suitably, the cell culture may produce nicotine.

[0270] In one embodiment there is provided the use of a cell culture, such as a harvested and / or processed cell culture, according to the invention for producing a tobacco industry product.

[0271] Tobacco cells harvested from in vitro culture can be dried, eg, freeze-dried, eg, to produce a powder.

[0272] In one embodiment, the cell culture is a tobacco cell culture. Those skilled in the art will recognize known methods for establishing in vitro cultures of tobacco cells. By way of example only, the following methods may be used: harvesting seeds form desired tobacco plants, sterilizing the outside of these seeds to remove undesirable organisms, planting the seeds to grow desired tobacco plants, removing tissue from tobacco plants (e.g., from tobacco stems) to use as explants, establishing callus cultures from tobacco explants, establishing cell suspension cultures from callus cultures, and harvesting culture materials (e.g., including tobacco cells) to produce tobacco cell cultures.

[0273] Tobacco cells can be harvested by a variety of methods, including filtration, e.g., vacuum filtration. The sample can be washed in the filter by adding water and the remaining liquid is removed by filtration, e.g., vacuum filtration.

[0274] The harvested tobacco cell culture can be further processed, for example dried, for example air dried and / or freeze dried. The harvested tobacco cell culture or the dried harvested tobacco cell culture or an extract thereof can be incorporated into a tobacco industry product according to the invention.

[0275] In one embodiment, the present invention provides a plant (e.g., a tobacco plant) or a part thereof for use in molecular agriculture. Suitably, a plant or a part thereof modified according to the present invention can be used in the production of proteins such as therapeutic substances, e.g., antibiotics, virus-like particles, nutraceuticals, or small molecules.

[0276] In one embodiment, the invention provides a method for producing a protein (e.g. a therapeutic protein), comprising modifying a plant or a part thereof capable of producing said protein (e.g. a therapeutic protein) by modulating (e.g. decreasing) the activity or expression of at least one galactose-1-phosphate uridyl transferase having an amino acid sequence as set forth in SEQ ID NO: 3, or a functional variant or functional fragment or orthologue thereof, or a sequence having at least 80% identity to SEQ ID NO: 3, or a homologue of SEQ ID NO: 3, or a nucleotide sequence as set forth in SEQ ID NO: 1 or 2, or a functional variant or functional fragment or orthologue of SEQ ID NO: 1 or 2, or a nucleic acid sequence having at least 80% identity to SEQ ID NO: 1 or 2, or a homologue of SEQ ID NO: 1 or 2, and culturing the plant under conditions sufficient to allow production of said protein (e.g. a therapeutic protein).

[0277] product The invention also provides products obtainable or obtained from plants according to the invention. Products are provided that are obtainable or obtained from plants in which the activity or expression of galactose-1-phosphate uridyltransferase is modulated.

[0278] In one embodiment, an article of manufacture may comprise a construct of the invention that modulates the activity or expression of at least one galactose-1-phosphate uridyl transferase as defined herein, hi one embodiment, an article of manufacture may comprise a construct of the invention that modulates the nucleic acid sequence of at least one galactose-1-phosphate uridyl transferase as defined herein.

[0279] The present invention also provides products obtainable or obtained from tobacco according to the present invention.

[0280] In one embodiment, there is provided a use of a tobacco plant of the present invention for producing tobacco leaves.

[0281] Suitably, the tobacco leaves may be subjected to downstream applications such as processing.

[0282] Thus, in one embodiment, use of the aforementioned embodiments may provide treated tobacco leaves. Suitably, the tobacco leaves may be dried, fermented, pasteurized, or a combination thereof. In another embodiment, the tobacco leaves may be cut. In some embodiments, the tobacco leaves may be cut before or after being dried, fermented, pasteurized, or a combination thereof.

[0283] In one embodiment, the present invention provides harvested leaves of a tobacco plant of the present invention.

[0284] In a further embodiment, harvested leaves can be obtained (eg, can be obtained) from tobacco plants propagated from propagation material of the present invention.

[0285] In another embodiment there is provided harvested leaves obtainable from the method or use of the present invention.

[0286] Suitably the harvested leaves may be cut harvested leaves.

[0287] In some embodiments, the harvested leaves may contain viable tobacco cells. In other embodiments, the harvested leaves may be subjected to further processing.

[0288] Processed tobacco leaf is also provided.

[0289] The treated tobacco leaves may be obtained from a tobacco plant of the present invention. Suitably, the treated tobacco leaves may be obtained from a tobacco plant obtained according to any method and / or use of the present invention.

[0290] Suitably, the treated leaves may have a reduced content of one or more TSNAs selected from NNN, NNK, NAT, and NAB. Suitably, the content of NNN may be reduced. Suitably, the content of NNK may be reduced. Suitably, the content of NAT may be reduced. Suitably, the content of NAB may be reduced. Suitably, the reduction in the TSNA content is compared to an equivalent product that has not been modified according to the present invention.

[0291] In another embodiment, the treated tobacco leaves can be obtained (eg, obtained) from a tobacco plant propagated from tobacco plant propagation material according to the present invention.

[0292] The treated tobacco leaves of the present invention can be obtained (eg, obtained) by treating the harvested leaves of the present invention.

[0293] As used herein, the term "treated tobacco leaf" refers to tobacco leaf that has been subjected to one or more processing steps that tobacco undergoes in the art. "Treatment of tobacco leaf" is free or substantially free of viable cells.

[0294] The term "viable cell" refers to a cell that is capable of proliferation and / or is metabolically active. Thus, when a cell is said to be not alive, also referred to as "non-viable," the cell does not exhibit the characteristics of a viable cell.

[0295] The term "substantially free of viable cells" means that less than about 5% of the total cells are viable. Preferably, less than about 3%, more preferably less than about 1%, and even more preferably less than about 0.1% of the total cells are viable.

[0296] In one embodiment, the treated tobacco leaves may be processed by one or more of curing, fermentation, and / or pasteurization.

[0297] Suitably, the treated tobacco leaves may be treated by drying.

[0298] The tobacco leaves may be dried by any method known in the art, in one embodiment, the tobacco leaves may be dried by one or more drying methods selected from the group consisting of air drying, flame drying, flue drying, and sun drying.

[0299] Suitably, the tobacco leaves may be air-dried.

[0300] Typically, air curing is done by hanging the tobacco leaves in a well-ventilated barn to dry. This usually takes place over a period of four to eight weeks. Air curing is particularly suited to burley tobacco.

[0301] Suitably, the tobacco leaves may be flue-cured, which is typically done by hanging the leaves in large barns where hardwood is kept burning with continuous or intermittent low-smoke, and usually takes between 3 days and 10 weeks, depending on the treatment and tobacco.

[0302] In another embodiment, the tobacco leaves may be flue-dried. Flue-dried may involve wrapping the tobacco leaves into tobacco sticks and hanging them from stepped poles in a drying barn. The barn usually has a flue leading from an externally fueled firebox. Typically, this results in heat-cured tobacco without exposure to smoke. Typically, the temperature is increased slowly during the drying process, and the entire process takes approximately one week.

[0303] Suitably, the tobacco leaves may be sun-cured, a process which typically involves exposing uncoated tobacco to sunlight.

[0304] Suitably, the treated tobacco leaves may be treated by fermentation.

[0305] Fermentation can be carried out in any manner known in the art. Typically, during fermentation, tobacco leaves are stacked into a pile of dried tobacco (bulk), which is covered, for example, with burlap to retain moisture. The combination of residual moisture inside the leaves and the weight of the tobacco creates natural heat, which mellows the tobacco. The temperature in the center of the bulk is monitored once a day. In some methods, the entire bulk is opened weekly. The leaves are then removed, shaken, moistened, and the bulk is turned to replace the inner and outer leaves of the bulk, bringing the bottom leaves to the top. This ensures even fermentation throughout the bulk. The additional moisture on the leaves and the actual turning of the leaves themselves creates heat, which releases the tobacco's natural ammonia and reduces nicotine, while also darkening the color and improving the tobacco's aroma. Typically, the fermentation process continues for up to six months, depending on the tobacco species, the position of the stem on the leaf, its thickness, and the intended use of the leaf.

[0306] Suitably, the treated tobacco leaf may be treated by pasteurization, which may be particularly preferred when the tobacco leaf is used to make smokeless tobacco industry products, most preferably snus.

[0307] Pasteurization of tobacco leaves can be carried out by any method known in the art, for example, as detailed in J Foulds, L Ramstrom, M Burke, K Fagerstrom. Effect of smokeless tobacco (snus) on smoking and public health in Sweden Tobacco Control (2003) 12: 349-359, the teachings of which are incorporated herein by reference.

[0308] In the production of snus, pasteurization is typically performed by heat treating the tobacco with steam (reaching a temperature of approximately 100° C.) for 24-36 hours. This results in a nearly sterile product, and without wishing to be bound by theory, one of the consequences of this is thought to be to limit further TSNA formation.

[0309] In one embodiment, the pasteurization may be steam pasteurization.

[0310] In some embodiments, the treated tobacco leaves may be cut. The treated tobacco leaves may be cut before or after treatment. Suitably, the treated tobacco leaves may be cut after treatment.

[0311] In one embodiment, the use of the foregoing embodiments may provide a reconstituted tobacco.

[0312] In one embodiment, a reconstituted tobacco is provided.

[0313] "Reconstituted" as used herein refers to tobacco material produced from tobacco leaves remaining after processing, which may also be called recon, which is recycled or homogenized sheet tobacco. Reconstituted tobacco allows for the production of consistent, high quality blends and allows for the control of the ratios of individual components.

[0314] The reconstituted tobacco can be a nanofiber recon (nanofibers can be extracted in solid or liquid form), a paper recon (which uses stems, flakes, and midribs as raw materials), or a slurry-type recon (which uses a mixture of fines and tobacco stems ground into a powder and mixed with water and a vegetable binder, and the soluble residue is formed into sheets by extracting the water).

[0315] Any method known in the art can be used to make reconstituted tobacco, see, e.g., CORESTA Congress, Sapporo, 2012, Smoke Science / Product Technology Groups, SSPT 12 (herein incorporated by reference).

[0316] In some embodiments, tobacco plants, harvested leaves of tobacco plants, and / or processed tobacco leaves can be used to extract nicotine. Extraction of nicotine can be carried out using any method known in the art. For example, the method for extracting nicotine from tobacco is taught in U.S. Patent No. 2,162,738, which is incorporated herein by reference.

[0317] In one aspect, the present invention provides a cured tobacco material made from a tobacco plant or part thereof according to the present invention.

[0318] Suitably, the cured tobacco may have a reduced content of one or more TSNAs selected from NNK, NNN, NAT, and NAB. Suitably, the content of NNN may be reduced. Suitably, the content of NNK may be reduced. Suitably, the content of NAT may be reduced. Suitably, the content of NAB may be reduced. Suitably, the reduced TSNA content is compared to an equivalent product that has not been modified according to the present invention.

[0319] In another aspect, the present invention provides a tobacco blend comprising a tobacco material produced from a tobacco plant or part thereof in accordance with the present invention or from a tobacco cell culture in accordance with the present invention. In one aspect, the present invention provides a tobacco blend comprising a dried tobacco material in accordance with the present invention.

[0320] Suitably, a tobacco blend according to the present invention may comprise approximately 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% tobacco derived from a tobacco plant or part thereof according to the present invention or a tobacco cell culture according to the present invention. Suitably, a tobacco blend may comprise approximately 10% tobacco derived from a tobacco plant or part thereof according to the present invention or a tobacco cell culture according to the present invention. Suitably, a tobacco blend may comprise approximately 20% tobacco derived from a tobacco plant or part thereof according to the present invention or a tobacco cell culture according to the present invention. Suitably, a tobacco blend may comprise approximately 30% tobacco derived from a tobacco plant or part thereof according to the present invention or a tobacco cell culture according to the present invention. Suitably, a tobacco blend may comprise approximately 40% tobacco derived from a tobacco plant or part thereof according to the present invention or a tobacco cell culture according to the present invention. Suitably, the tobacco blend may comprise approximately 50% tobacco derived from a tobacco plant or part thereof in accordance with the present invention or a tobacco cell culture in accordance with the present invention. Suitably, the tobacco blend may comprise approximately 60% tobacco derived from a tobacco plant or part thereof in accordance with the present invention or a tobacco cell culture in accordance with the present invention. Suitably, the tobacco blend may comprise approximately 70% tobacco derived from a tobacco plant or part thereof in accordance with the present invention or a tobacco cell culture in accordance with the present invention. Suitably, the tobacco blend may comprise approximately 80% tobacco derived from a tobacco plant or part thereof in accordance with the present invention or a tobacco cell culture in accordance with the present invention. Suitably, the tobacco blend may comprise approximately 90% tobacco derived from a tobacco plant or part thereof in accordance with the present invention or a tobacco cell culture in accordance with the present invention.

[0321] In one embodiment, a tobacco blend product of the present invention comprises at least about 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 95 dry weight percent of cured tobacco from a tobacco plant or part thereof in accordance with the present invention or from a tobacco cell culture in accordance with the present invention.

[0322] Suitably, the dried tobacco material may be air dried. Suitably, the dried tobacco material may be flue dried. Suitably, the dried tobacco material may be sun dried. Suitably, the dried tobacco material may be flame dried.

[0323] Tobacco industry products or smoking articles according to the invention may comprise tobacco materials (eg, dried tobacco materials or reconstituted tobacco materials) according to the invention.

[0324] In another aspect, the present invention provides a tobacco industry product.

[0325] In one embodiment, the tobacco industry product according to the present invention may be a blended tobacco industry product. Suitably, the tobacco blend may comprise a dried tobacco material according to the present invention.

[0326] In one embodiment, a tobacco industry product can be prepared from a tobacco plant or part thereof of the present invention.

[0327] Suitably, a tobacco plant or part thereof can be propagated from tobacco plant propagation material according to the present invention.

[0328] As used herein, the term "part thereof" in the context of a tobacco plant refers to a part of the tobacco plant. Suitably, the "part thereof" may be the leaves, roots, or stems, or flowers, of the tobacco plant. Suitably, the "part thereof" may be the leaves, roots, or stems of the tobacco plant.

[0329] Tobacco Industry Products As used herein, the term "tobacco industry products" includes combustible smoking articles, such as cigarettes, cigarillos, cigars, pipe or hand-rolled cigarettes (whether based on tobacco, tobacco derivatives, expanded tobacco, reconstituted tobacco, tobacco substitutes, or other smokable materials), non-combustible aerosol delivery systems, such as heating products that release compounds from a substrate material without combustion, such as hybrid systems for generating aerosols from combinations of substrate materials, e.g., hybrid systems containing liquid or gel-like or solid substrates, and aerosolizable substrate materials used in conjunction with these aerosol delivery systems; and aerosol-free delivery articles, which may or may not deliver nicotine, such as lozenges, gums, patches, respirable powder-containing articles, and smokeless tobacco industry products, such as snuff and snuff.

[0330] In one embodiment, a tobacco industry product can be prepared from (eg, can include) a tobacco plant or part thereof of the present invention.

[0331] Suitably, a tobacco plant or part thereof can be propagated from tobacco plant propagation material according to the present invention.

[0332] As used herein, the term "part thereof" in the context of a tobacco plant refers to a part of the tobacco plant. Preferably, the "part thereof" is a leaf of the tobacco plant.

[0333] In another embodiment, tobacco industry products can be prepared from the harvested leaves of the present invention.

[0334] In a further embodiment, tobacco industry products can be prepared from the treated tobacco leaves of the present invention.

[0335] Suitably, the tobacco industry product may be prepared from tobacco leaves that have been treated by one or more of: curing, fermentation, and / or pasteurization.

[0336] Suitably, the tobacco industry product may include cut tobacco leaves, which may have been processed as per the previous embodiments.

[0337] In another embodiment, tobacco industry products can be prepared from the tobacco cell cultures according to the present invention.

[0338] In another embodiment, a tobacco industry product may be prepared from (eg, may include) dried tobacco material according to the present invention.

[0339] In another embodiment, a tobacco industry product may be prepared from (eg, may include) a tobacco blend according to the present invention.

[0340] In one embodiment, the tobacco industry product may be a smoking article.

[0341] As used herein, the term "smoking article" may include smokable products such as cigarettes, cigarettes, cigars, and cigarillos, whether based on tobacco, tobacco derivatives, expanded tobacco, reconstituted tobacco, or tobacco substitutes.

[0342] In another embodiment, the tobacco industry product may be a smokeless tobacco industry product.

[0343] As used herein, the term "smokeless tobacco industry product" refers to a tobacco industry product that is designed not to produce smoke and / or be burned.

[0344] Smokeless tobacco industry products (including heat-not-burn materials) may contain tobacco in any form, including dry particles, strips, granules, powders, or slurries, placed on, mixed with, surrounded by, or combined with other components in any form, such as flakes, films, tabs, foams, or beads.

[0345] In one embodiment, the smokeless tobacco industry products may include snus, snuff, chewing tobacco, or the like.

[0346] In one embodiment, the tobacco industry product is a combustible smoking article selected from the group consisting of cigarettes, cigarillos, and cigars.

[0347] In one embodiment, the tobacco industry product comprises one or more components of a combustible smoking article, such as a filter, a filter rod, a filter rod segment, a tobacco, a tobacco rod, a tobacco rod segment, a splice, an additive release component, such as a capsule, a thread, a bead, a paper, such as plug wrap, tipping paper, or cigarette paper.

[0348] In one embodiment, the tobacco industry product is a non-combustible aerosol delivery system.

[0349] In one embodiment, the tobacco industry product includes one or more components of a non-combustible aerosol delivery system, such as a heater and an aerosolizable substrate.

[0350] In one embodiment, the aerosol delivery system is an electronic cigarette, also known as a vaping device.

[0351] In one embodiment, the electronic cigarette includes a heater, a power source capable of providing power to the heater, an aerosolizable substrate such as a liquid or gel, a housing, and may include a mouthpiece.

[0352] In one embodiment, the aerosolizable substrate is contained in a substrate container, hi one embodiment, the substrate container is combined with or includes a heater.

[0353] In one embodiment, the tobacco industry product is a heating product that releases one or more compounds by heating, without burning, a substrate material. The substrate material is an aerosolizable material that may be, for example, tobacco or other non-tobacco products that may or may not contain nicotine. In one embodiment, the heating product is a tobacco heating product.

[0354] In one embodiment, the heating product is an electronic device.

[0355] In one embodiment, the tobacco heating product includes a heater, a power source capable of providing power to the heater, and an aerosolizable substrate, such as a solid or gel-like material.

[0356] In one embodiment, the heating product is a non-electronic product.

[0357] In one embodiment, the heating product includes an aerosolizable substrate, such as a solid or gel-like material, and a heat source capable of providing thermal energy to the aerosolizable substrate without the use of any electronic means, for example by burning a combustion material, such as charcoal.

[0358] In one embodiment, the heating product also includes a filter capable of filtering the aerosol generated by heating the aerosolizable substrate.

[0359] In some embodiments, the aerosolizable matrix material may include a vapor or aerosol generating agent or a humectant such as glycerol, propylene glycol, triacetin, or diethylene glycol.

[0360] In one embodiment, the tobacco industry product is a hybrid system for generating an aerosol by heating, without burning, a combination of substrate materials. The substrate materials may include, for example, solids, liquids, or gels, which may or may not contain nicotine. In one embodiment, the hybrid system includes a liquid or gel substrate and a solid substrate. The solid substrate may be, for example, tobacco or other non-tobacco products, which may or may not contain nicotine. In one embodiment, the hybrid system includes a liquid or gel substrate and tobacco.

[0361] In further embodiments, the tobacco industry product may be a tobacco heating device or a hybrid device or an e-cigarette or the like.

[0362] Typically, in tobacco heating devices or hybrid devices, the aerosol is generated by the conduction of heat from a heat source to a physically separate aerosol-forming substrate or material that may be located in, around, or downstream from the heat source. During smoking, volatile compounds are released from the aerosol-forming substrate by heat conduction from the heat source and are carried along with the air drawn through the smoking article. As the released compounds cool, they condense to form an aerosol, which is inhaled by the user.

[0363] Aerosol generating articles and devices for consuming or smoking tobacco heating devices are known in the art. These may include, for example, electrically heated aerosol generating devices, where the aerosol is generated by the conduction of heat from one or more electrical heating elements of the aerosol generating device to an aerosol-forming substrate of the tobacco heating device.

[0364] Suitably, the tobacco heating device may be an aerosol generating device.

[0365] Preferably, the tobacco heating device may be a heated device, which are known in the art and release compounds by heating tobacco without burning it.

[0366] Examples of suitable heated devices may be those taught in WO 2013 / 034459 or GB 2515502, which are incorporated herein by reference.

[0367] In one embodiment, the aerosol-forming substrate of the tobacco heating device may be a tobacco industry product according to the present invention.

[0368] In one embodiment, the tobacco heating device may be a hybrid device.

[0369] Polynucleotides / Polypeptides / Constructs In certain embodiments of the invention, a construct that modulates the activity or expression of at least one galactose-1-phosphate uridyl transferase as described herein may be transformed into a plant cell, suitably under the direction of a promoter.

[0370] In certain embodiments of the present invention, at least one of the constructs described herein that reduce (i.e. inhibit) the activity or expression of galactose-1-phosphate uridyl transferase can be transformed into plant cells under the direction of a promoter.For example, the gene construct can be a gene editing construct, or can include an RNAi molecule, which can include a small interfering RNA (siRNA) molecule or a short hairpin loop (shRNA) molecule.

[0371] In certain embodiments of the invention, constructs that increase the activity or expression of a gene encoding a galactose-1-phosphate uridyl transferase as described herein, e.g., a construct encoding a gene encoding a galactose-1-phosphate uridyl transferase, such as an endogenous galactose-1-phosphate uridyl transferase, can be transformed into a plant cell, suitably under the direction of a promoter.

[0372] The construct can be introduced into a plant according to the invention by a suitable vector, for example a plant transformation vector. The plant transformation vector may include an expression cassette comprising in the transcriptional direction 5' to 3', a promoter sequence, a construct sequence targeting a gene encoding galactose-1-phosphate uridyl transferase as described herein, and may include a 3' untranslated terminator sequence comprising a termination signal for RNA polymerase and a polyadenylation signal for polyadenylases. The promoter sequence may be present in one or more copies, such copies may be identical to or variants of the promoter sequences as described above. Terminator sequences may be obtained from plant, bacterial or viral genes. Suitable terminator sequences are, for example, the pea rbcS E9 terminator sequence, the nos terminator sequence derived from the nopaline synthase gene of Agrobacterium tumefaciens, and the 35S terminator sequence derived from the cauliflower mosaic virus. Those skilled in the art will readily recognize other suitable terminator sequences.

[0373] The constructs of the invention may also include gene expression enhancing mechanisms to increase the strength of the promoter. An example of such an enhancer element is that derived from part of the promoter of the pea plastocyanin gene, which is the subject of International Patent Application WO 97 / 20056, which is incorporated herein by reference. Suitable enhancer elements may be, for example, the nos enhancer element derived from the nopaline synthase gene of Agrobacterium tumefaciens, and the 35S enhancer element derived from the cauliflower mosaic virus.

[0374] These regulatory regions may be derived from the same gene as the promoter DNA sequence or may be derived from different genes, from Nicotiana tabacum or other organisms, such as Solanaceae or Cestroideae. All regulatory regions should be operable in the cells of the tissue to be transformed.

[0375] The promoter DNA sequence may be derived from the desired gene, e.g. the gene which the promoter is intended to direct, e.g. the gene encoding galactose-1-phosphate uridyl transferase according to the invention, the same gene as the coding sequence used in the present invention, or it may be derived from a different gene, e.g. from Nicotiana tabacum or another organism, e.g. from the Solanaceae or the subfamily Nosicaceae.

[0376] The expression cassette can be incorporated into a basic plant transformation vector such as pBIN 19 Plus, pBI 101, pKYLX71:35S2, pCAMBIA2300, or other suitable plant transformation vectors known in the art. The plant transformation vector will contain such sequences in addition to the expression cassette as they are necessary for the transformation process. These sequences may include Agrobacterium vir genes, one or more T-DNA border sequences, and a selectable marker or other means of identifying transgenic plant cells.

[0377] The term "expression vector or plant transformation vector" refers to a construct capable of in vivo or in vitro expression. Preferably, the expression vector is integrated into the genome of an organism. In one embodiment, the vector of the invention expresses a protein, such as the galactose-1-phosphate uridyl transferase described herein. The term "integrated" preferably relates to stable integration into the genome.

[0378] Techniques for transforming plants are well known in the art and include, for example, Agrobacterium-mediated transformation. The basic principle in the construction of genetically modified plants is to insert genetic information into the plant genome to obtain stable maintenance of the inserted genetic material. A general overview of the technique can be found in the articles by Potrykus (Annu Rev Plant Physiol Plant Mol Biol

[1991] 42:205-225) and Christon (AgroFood-Industry Hi-Tech March / April1994 17-27), which are incorporated herein by reference.

[0379] Typically, in Agrobacterium-mediated transformation, a binary vector carrying the desired foreign DNA, i.e., a construct according to the invention, is transferred from an appropriate Agrobacterium strain to a target plant by co-cultivating Agrobacterium with an explant derived from the target plant. The transformed plant tissue is then regenerated on a selection medium containing a selectable marker and a plant growth hormone. An alternative method is the floral dip method (Clough & Bent, 1998 Plant J. 1998 Dec;16(6):735-43, incorporated herein by reference), in which flower buds of intact plants are contacted with a suspension of an Agrobacterium strain containing a chimeric gene, and after seed production, transformed individuals are allowed to germinate and identified by growth on a selection medium. Direct infection of plant tissue with Agrobacterium is a widely used and simple technique, which is described in Butcher et al. (1980) Tissue Culture Methods for Plant Pathologists, eds.: DS Ingrams and JP Helgeson, 203-208, incorporated herein by reference.

[0380] Further suitable transformation methods include direct gene transfer into protoplasts, for example, using polyethylene glycol or electroporation techniques, particle guns, microinjection, and the use of silicon carbide fibers. Transformation of plants using ballistic transformation and generation of fertile transgenic maize plants by silicon carbide whisker-mediated transformation are taught in Frame et al. (1994) The Plant Journal 6(6): 941-948, which is incorporated herein by reference, and viral transformation techniques are taught in Meyer et al. (1992) Mol. Gen. Genet. 231(3): 345-352, which is incorporated herein by reference. The use of cassava mosaic virus as a vector system for plants is taught in Meyer et al. (1992) Gene 110: 213-217, which is incorporated herein by reference. Further teachings on plant transformation can be found in EP 0 449 375, which is incorporated herein by reference.

[0381] In a further aspect, the present invention relates to a vector system that carries the construct and introduces it into the genome of an organism such as a plant, suitably a tobacco plant. The vector system may contain one vector, but may also contain two vectors. In the case of two vectors, the vector system is usually called a binary vector system. The binary vector system is described in more detail in Gynheung et al. (1980) Binary Vectors, Plant Molecular Biology Manual A3, 1-19, which is incorporated herein by reference.

[0382] One widely used plant cell transformation system uses the Ti plasmid from Agrobacterium tumefaciens or the Ri plasmid from Agrobacterium rhizogenes, described by An et al. (1986) Plant Physiol. 81, 301-305, and Butcher et al. (1980) Tissue Culture Methods for Plant Pathologists eds.: DS Ingrams and JP Helgeson, 203-208, which are incorporated herein by reference. After each method of introduction of the desired exogenous gene according to the present invention in plants, the presence and / or insertion of additional DNA sequences may be necessary. The use of T-DNA for the transformation of plant cells has been intensively studied and is described in EP 120516 A1, Hoekema (1985) The Binary Plant Vector System, Offset-drukkerij Kanters BB, Amsterdam Chapter V, Fraley et al. Crit. Rev. Plant Sci. 4:1-46, and An et al. (1985) EMBO J 4: 277-284, all of which are incorporated herein by reference.

[0383] Plant cells transformed with constructs that modulate the activity or expression of at least one galactose-1-phosphate uridyltransferase can be grown and maintained according to well-known tissue culture methods, for example by culturing the cells in an appropriate culture medium supplemented with essential growth factors such as amino acids, plant hormones, vitamins, etc.

[0384] The term "transgenic plant" in the context of the present invention includes any plant that comprises a construct that modulates the activity or expression of at least one galactose-1-phosphate uridyltransferase according to the present invention. Thus, a transgenic plant is a plant that has been transformed with a construct according to the present invention. Preferably, the transgenic plant exhibits a modulated (e.g., reduced) alkaloid content and / or a modulated (e.g., reduced) TSNA precursor content according to the present invention. The term "transgenic plant" does not refer to a native nucleotide coding sequence in its natural environment, i.e. under the control of its native promoter (which is also in its natural environment).

[0385] In one embodiment, the gene, construct, plant transformation vector, or plant cell encoding galactose-1-phosphate uridyl transferase according to the invention is in isolated form. The term "isolated" means that the sequence is at least substantially free of at least one other component with which the sequence is naturally associated and found in nature in its natural state.

[0386] In one embodiment, the gene, construct, plant transformation vector, or plant cell encoding galactose-1-phosphate uridyl transferase according to the invention is in a purified form. The term "purified" means in a relatively pure state, e.g., at least about 90% pure, or at least about 95% pure, or at least about 98% pure.

[0387] The term "nucleotide sequence" as used herein refers to an oligonucleotide or polynucleotide sequence, as well as variants, homologues, fragments, and derivatives thereof, such as portions thereof. Nucleotide sequences may be of genomic or synthetic or recombinant origin, and they may be double-stranded or single-stranded, representing either the sense or antisense strand.

[0388] The term "nucleotide sequence" in relation to the present invention includes genomic DNA, cDNA, synthetic DNA and RNA. Preferably, the nucleotide sequence refers to a DNA sequence encoding the present invention, more preferably a cDNA sequence.

[0389] In a preferred embodiment, the nucleotide sequence in relation to and as such within the scope of the present invention, i.e. the gene encoding the galactose-1-phosphate uridyl transferase according to the present invention, includes the native nucleotide sequence in its natural environment and linked to the sequence with which it is naturally associated (which is also in its natural environment). For ease of reference, we refer to this preferred embodiment as the "native nucleotide sequence". In this regard, the term "native nucleotide sequence" refers to the entire nucleotide sequence in its native environment and operably linked to the entire promoter with which it is naturally associated (which promoter is also in its native environment).

[0390] The nucleotide sequence for use in the present invention may be present in a vector in which the nucleotide sequence is operably linked to a regulatory sequence capable of providing expression of the nucleotide sequence by a suitable host organism. The construct for use in the present invention may be transformed into a suitable host cell as described herein to provide expression of the polypeptide of the present invention. The selection of a vector, such as a plasmid, cosmid, or phage vector, often depends on the host cell into which it is introduced. The vector may be used in vitro, for example for the production of RNA, or may be used to transfect, transform, transduce, or infect a host cell.

[0391] In some applications, the nucleotide sequence for use in the present invention is operably linked to a regulatory sequence that can provide for expression of the nucleotide sequence by, for example, a selected host cell. By way of example, the present invention encompasses a vector comprising the nucleotide sequence of the gene encoding galactose-1-phosphate uridyl transferase described herein operably linked to such a regulatory sequence, i.e., the vector is an expression vector.

[0392] The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A regulatory sequence "operably linked" to a coding sequence is ligated such that expression of the coding sequence is achieved under conditions compatible with the control sequences.

[0393] The term "regulatory sequence" includes promoters and enhancers and other expression regulation signals. The term "promoter" is used in its usual sense in the art, for example, an RNA polymerase binding site. The nucleotide sequence in the construct encoding galactose-1-phosphate uridyl transferase may be operably linked to at least one promoter.

[0394] The term "construct" is synonymous with terms such as "cassette" or "vector," but includes a nucleotide sequence for use in accordance with the present invention linked directly or indirectly to a promoter.

[0395] An example of an indirect linkage is the provision of a suitable spacer group, such as an intron sequence, such as the Sh1-intron or the ADH intron, between the promoter and the nucleotide sequence of the invention. The same applies to the term "fused" in the context of the present invention, including direct or indirect linkage. In some cases, the term does not refer to the natural combination of the nucleotide sequence encoding the protein normally associated with the wild-type gene promoter, when both are in their natural environment. The construct may further contain or express a marker, which allows for the selection of the genetic construct.

[0396] In some embodiments, the promoter may be operably linked to a nucleotide sequence in a construct or vector used to regulate the concentration and / or total nicotine content in a cell or cell culture, or a tobacco plant or portion thereof.

[0397] In some embodiments, the promoter may be selected from the group consisting of a constitutive promoter, a tissue-specific promoter, a developmentally-regulated promoter, and an inducible promoter.

[0398] In one embodiment, the promoter may be a constitutive promoter.

[0399] A constitutive promoter directs expression of a gene throughout various parts of the plant continuously during plant development, although the gene may not be expressed at the same level in all cell types. Examples of known constitutive promoters include those associated with the cauliflower mosaic virus 35S transcript (Odell JT, Nagy F, Chua NH. (1985). Identification of DNA sequences required for activity of the cauliflower mosaic virus 35S promoter. Nature. 313 810-2), the rice actin 1 gene (Zhang W, McElroy D, Wu R. (1991). Analysis of rice Act1 5' region activity in transgenic rice plants. Plant Cell 3 1155-65), and the maize ubiquitin 1 gene (Cornejo MJ, Luth D, Blankenship KM, Anderson OD, Blechl AE. (1993). Activity of a maize ubiquitin promoter in transgenic rice. Plant Molec. Biol. 23 567-81). Constitutive promoters such as the Carnation Etched Ring Virus (CERV) promoter (Hull R, Sadler J, Longstaff M (1986) (CaMV / 35S), figwort mosaic virus 35S promoter. The sequence of carnation etched ring virus DNA: comparison with cauliflower mosaic virus and retroviruses. EMBO Journal, 5(2):3083-3090).

[0400] The constitutive promoter may be selected from the carnation etched ring virus (CERV) promoter, the cauliflower mosaic virus (CaMV) 35S promoter, the rice actin 1 gene or the promoter derived from the maize ubiquitin 1 gene.

[0401] The promoter may be a tissue-specific promoter. A tissue-specific promoter is one that directs the expression of a gene in a part (or a few parts) of a plant, usually throughout the life of those plant parts. The category of tissue-specific promoters generally includes promoters whose specificity is not absolute, i.e., they may also direct lower levels of expression in tissues other than the preferred tissue. Tissue-specific promoters include the phaseolin promoter, legumin b4 promoter, usp promoter, sbp promoter, ST-LS1 promoter, and B33 (patatin class I promoter).

[0402] In another embodiment, the promoter may be a developmentally-regulated promoter.

[0403] A developmentally-regulated promoter directs a change in expression of a gene in one or more parts of a plant at a particular time during plant development. The gene may be expressed at different (usually lower) levels in that plant part at other times and may also be expressed in other plant parts.

[0404] In one embodiment, the promoter may be an inducible promoter.

[0405] An inducible promoter can direct the expression of a gene in response to an inducer. In the absence of the inducer, the gene is not expressed. The inducer can act directly on the promoter sequence or by counteracting the effect of a repressor molecule. The inducer can be a metabolite, a protein, a growth regulator (such as auxin and salicylic acid, which activate the OCS promoter), or a chemical such as a toxic element, a physiological stress such as heat, light (such as the soybean SSU promoter), wounding (e.g., nos, the nopaline synthase promoter), or osmotic pressure, or an indirect result of the action of a pathogen or pest. Developmentally regulated promoters can be described as a specific type of inducible promoter that responds to endogenous inducers produced by the plant or to environmental stimuli at specific points in the plant's life cycle. Examples of known inducible promoters include those associated with wound response such as those described by Warner SA, Scott R, Draper J. ((1993) Plant J. 3 191-201), those associated with temperature response as disclosed by Benfey and Chua (1989) (Benfey, PN, and Chua, NH. ((1989) Science 244 174-181), and those that are chemically induced as described by Gatz ((1995) Methods in Cell Biol. 50 411-424).

[0406] Nucleotide sequences encoding either proteins having the specific properties of genes encoding galactose-1-phosphate uridyl transferase as defined herein or proteins suitable for modification can be identified and / or isolated and / or purified from any cell or organism producing said proteins. Various methods for identifying and / or isolating and / or purifying nucleotide sequences are well known in the art. By way of example, once a suitable sequence has been identified and / or isolated and / or purified, PCR amplification techniques can be used to prepare two or more sequences.

[0407] In yet a further alternative, nucleotide sequences encoding galactose-1-phosphate uridyl transferase can be prepared synthetically by established standard methods, such as the phosphoramidite method described by Beucage et al. (1981) Tetrahedron Letters 22, 1859-1869, herein incorporated by reference, or the method described by Matthes et al. (1984) EMBO J. 3, 801-805, herein incorporated by reference. In the phosphoramidite method, oligonucleotides are synthesized, for example in an automatic DNA synthesizer, purified, annealed, ligated, and cloned into an appropriate vector.

[0408] As used herein, the term "amino acid sequence" is synonymous with the term "polypeptide" and / or the term "protein." In some cases, the term "amino acid sequence" is synonymous with the term "peptide." In some cases, the term "amino acid sequence" is synonymous with the term "enzyme."

[0409] The present invention also encompasses the use of amino acid sequences or any nucleotide sequences of polypeptides having specific properties defined herein, i.e. sequences having a certain degree of sequence identity or sequence homology with the gene encoding galactose-1-phosphate uridyl transferase (hereinafter referred to as "homologous sequences"). Here, the term "homolog" refers to an entity having a certain degree of homology with the subject amino acid sequence and the subject nucleotide sequence. Here, the term "homology" can be considered as equivalent to "identity".

[0410] Homologous amino acid and / or nucleotide sequences and / or fragments should provide and / or code for polypeptides that retain and / or enhance the functional activity of galactose-1-phosphate uridyl transferase. Typically, a homologous sequence contains or codes for, for example, the same catalytic site as the amino acid sequence of interest. Although homology can be considered in terms of similarity (i.e., amino acid residues having similar chemical properties / functions), in the context of the present invention, it is preferred to express homology in terms of sequence identity. Homologous sequences typically retain functional domains or motifs.

[0411] In one embodiment, a homologous sequence comprises an amino acid or nucleotide sequence that has one, two or more additions, deletions and / or substitutions compared to the reference sequence.

[0412] In one embodiment, homologs of galactose-1-phosphate uridyl transferase SEQ ID NO:3 are provided in Table 1. The present invention extends to the use of the homologs listed in Table 1, and sequences having at least 80% sequence identity thereto.

[0413] Sequence identity Comparison of sequence identity can be performed by eye, or more commonly, with the aid of readily available sequence comparison programs. These commercially available computer programs can calculate the percent homology between two or more sequences. The percent homology or identity can be calculated over a contiguous sequence, i.e., one sequence is aligned with the other, and each amino acid in one sequence is directly compared, one residue at a time, with the corresponding amino acid in the other sequence. This is called an "ungapped" alignment. Typically, such ungapped alignments are performed only over a relatively small number of residues.

[0414] Although this is a very simple and consistent method, it cannot take into account, for example, that in an otherwise identical pair of sequences, a single insertion or deletion can occur at a subsequent amino acid residue, thus upsetting the alignment and thus greatly reducing the percent homology when a full alignment is performed. As a result, most sequence comparison methods are designed to produce optimal alignments that take into account possible insertions and deletions without unduly penalizing the overall homology score. This is achieved by inserting "gaps" in the sequence alignment to maximize local homology.

[0415] However, these more sophisticated methods assign a "gap penalty" to each gap that occurs in the alignment, such that, in the case of the same number of identical amino acids, a sequence alignment with as few gaps as possible (which reflects a higher relatedness between the two compared sequences) will achieve a higher score than one with many gaps. An "affine gap cost" is typically used, which imposes a relatively high cost on the presence of a gap and a smaller penalty on each subsequent residue within the gap. This is the most commonly used gap scoring system. High gap penalties naturally result in optimized alignments with fewer gaps. Most alignment programs allow the gap penalties to be modified. However, it is preferred to use the default values ​​when using such software for sequence comparisons.

[0416] Calculation of maximum homology percentage therefore first requires providing an optimal alignment, taking into account gap penalties. A suitable computer program for performing such an alignment is Vector NTI (Invitrogen Corp.). Examples of software capable of performing sequence comparison include, but are not limited to, the BLAST package (see Ausubel et al. (1999) Short Protocols in Molecular Biology, 4th Ed - Chapter 18), BLAST2 (see FEMS Microbiol Lett 1999 174(2): 247-50, FEMS Microbiol Lett 1999 177(1): 187-8, and tatiana@ncbi.nlm.nih.gov), FASTA (Altschul et al. 1990 J. Mol. Biol. 403-410), and AlignX. At least BLAST, BLAST2, and FASTA are available for offline and online searching (see Ausubel et al. 1999, pages 7-58 to 7-60).

[0417] Although the final % homology can be measured in terms of identity, the alignment process itself is typically not based on an all-or-nothing pairwise comparison. Instead, a scaled similarity score matrix is ​​commonly used that assigns a score to each pairwise comparison based on chemical similarity or evolutionary distance. An example of such a matrix commonly used is the BLOSUM62 matrix, which is the default matrix for the BLAST suite of programs. Vector NTI programs typically use either the published default values, or, if provided, custom symbol comparison tables (see user manual for further details). For some applications, it is preferred to use the default values ​​of the Vector NTI package.

[0418] Alternatively, the percentage homology can be calculated using the multiple alignment feature in Vector NTI (Invitrogen Corp.), based on an algorithm similar to CLUSTAL (Higgins DG & Sharp PM (1988), Gene 73(1), 237-244). Once the software has produced an optimal alignment, it is possible to calculate % homology, preferably % sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result.

[0419] If gap penalties are used in determining sequence identity, the following parameters are preferably used for pairwise alignments:

[0420] [Table 2]

[0421] [Table 3]

[0422] In one embodiment, CLUSTAL can be used with a set of gap penalties and gap extensions as defined above. In some embodiments, the gap penalties used for BLAST or CLUSTAL alignments can be different from those detailed above. Those skilled in the art will understand that standard parameters for performing BLAST and CLUSTAL alignments can change periodically, and can select appropriate parameters based on the detailed standard parameters for the BLAST or CLUSTAL alignment algorithms at that time.

[0423] Suitably the degree of identity for nucleotide sequences is determined over at least 50 contiguous nucleotides, preferably over at least 60 contiguous nucleotides, preferably over at least 70 contiguous nucleotides, preferably over at least 80 contiguous nucleotides, preferably over at least 90 contiguous nucleotides, preferably over at least 100 contiguous nucleotides, preferably over at least 150 contiguous nucleotides, preferably over at least 200 contiguous nucleotides, preferably over at least 250 contiguous nucleotides, preferably over at least 300 contiguous nucleotides, preferably over at least 350 contiguous nucleotides, preferably over at least 400 contiguous nucleotides, preferably over at least 450 contiguous nucleotides, preferably over at least 500 contiguous nucleotides, preferably over at least 550 contiguous nucleotides, preferably over at least 600 contiguous nucleotides, preferably over at least 650 contiguous nucleotides or preferably over at least 700 contiguous nucleotides.

[0424] Suitably the degree of identity for nucleotide, cDNA, cds or amino acid sequences may be determined over the entire sequence.

[0425] The sequences may also have deletions, insertions, or substitutions of amino acid residues which result in silent changes resulting in a functionally equivalent substance. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or amphipathic nature of the residues, so long as the secondary binding activity of the substance is retained. For example, negatively charged amino acids include aspartic acid and glutamic acid, positively charged amino acids include lysine and arginine, and amino acids having uncharged polar head groups with similar hydrophilicity values ​​include leucine, isoleucine, valine, glycine, alanine, asparagine, glutamine, serine, threonine, phenylalanine, and tyrosine.

[0426] Conservative substitutions can be made, for example, according to the following table: Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other.

[0427] [Table 4]

[0428] The invention also encompasses homologous substitutions (both substitution and replacement are used herein to mean the replacement of an existing amino acid residue with an alternative residue) that may occur, i.e., basic to basic, acidic to acidic, polar to polar, etc. Non-homologous substitutions may also occur, i.e., the substitution of one class of residue for another class of residue, or instead, substitutions involving the inclusion of unnatural amino acids such as ornithine (hereinafter referred to as Z), diaminobutyric acid ornithine (hereinafter referred to as B), norleucine ornithine (hereinafter referred to as O), pyriylalanine, thienylalanine, naphthylalanine, and phenylglycine.

[0429] The replacement also works with alpha * and alpha disubstituted * Amino acids, N-alkyl amino acids * , lactic acid * , halide derivatives of natural amino acids, e.g., trifluorotyrosine * , p-Cl-phenylalanine * , p-Br-phenylalanine * , pI-phenylalanine * , L-allyl-glycine * , β-alanine * , L-α-aminobutyric acid * , L-γ-aminobutyric acid * , L-α-aminoisobutyric acid * , L-ε-aminocaproic acid # , 7-aminoheptanoic acid * , L-methionine sulfone #* , L-norleucine *, L-Norvaline * , p-nitro-L-phenylalanine * , L-hydroxyproline # , L-thioproline * , methyl derivatives of phenylalanine (Phe), e.g., 4-methyl-Phe * , Pentamethyl-Phe * , L-Phe(4-amino) # , L-Tyr(methyl) * , L-Phe(4-isopropyl) * , L-Tic (1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) * , L-diaminopropionic acid # , and L-Phe(4-benzyl) * This can be accomplished with unnatural amino acids, including * is used for the purposes of the above discussion (for either homologous or non-homologous substitutions) to indicate the hydrophobicity of the derivative, while # is used to indicate the hydrophilicity of the derivative, and # * shows amphiphilic characteristics.

[0430] The variant amino acid sequence may include an amino acid spacer such as a glycine or β-alanine residue, as well as a suitable spacer group, including an alkyl group such as a methyl, ethyl, or propyl group, that may be inserted between any two amino acid residues of the sequence. A further variation involves the presence of one or more amino acid residues in peptoid form, which will be well understood by those skilled in the art. For the avoidance of doubt, "peptoid form" is used to refer to variant amino acid residues in which the nitrogen atom of the residue has an α-carbon substituent rather than an α-carbon. Methods for preparing peptides in peptoid form are known in the art, for example, Simon et al. (1992) PNAS 89(20), 9367-9371, and Horwell (1995) Trends Biotechnol. 13(4), 132-134.

[0431] The nucleotide sequences for use in the present invention may contain synthetic or modified nucleotides therein. Several different types of modifications to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones, and / or the addition of acridine or polylysine chains at the 3' and / or 5' ends of the molecule. For the purposes of the present invention, it is understood that the nucleotide sequences described herein may be modified by any method available in the art. Such modifications may be made to enhance the in vivo activity or life span of the nucleotide sequences of the present invention.

[0432] The present invention also encompasses sequences that are complementary to the nucleic acid sequences of the present invention, or sequences that can hybridize to either the sequences of the present invention or to sequences complementary thereto. As used herein, the term "hybridization" includes "the process by which a strand of nucleic acid joins with a complementary strand through base pairing" and the amplification process carried out in polymerase chain reaction (PCR) techniques.

[0433] The present invention also relates to nucleotide sequences that can hybridize to the nucleotide sequences of the present invention (including the complementary sequences of the sequences presented herein). Preferably, hybridization is determined under stringent conditions (e.g., 50° C. and 0.2×SSC {1×SSC=0.15M NaCl, 0.015M NaCitrate, pH 7.0}). More preferably, hybridization is determined under high stringency conditions (e.g., 65° C. and 0.1×SSC {1×SSC=0.15M NaCl, 0.015M NaCitrate, pH 7.0}).

[0434] Reviews of general techniques used in plant transformation can be found in articles such as Potrykus et al. (1991) Annu Rev Plant Physiol. Plant Mol. Biol. 42:205-225, and Christou et al. (1994) Agro-Food-Industry Hi-Tech March / April 17-27, which are incorporated herein by reference. Further teachings on plant transformation can be found in European Patent Application Publication No. 0 449 375, which is incorporated herein by reference.

[0435] Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Singleton, et al., DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY, 20 ED., John Wiley and Sons, New York (1994), and Hale & Marham, THE HARPER COLLINS DICTIONARY OF BIOLOGY, Harper Perennial, NY (1991) provide those of ordinary skill in the art with a general dictionary for many of the terms used in this disclosure.

[0436] The disclosure is not limited by the exemplary methods and materials disclosed herein, and any methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the present disclosure. Numeric ranges are inclusive of the numbers defining the range. Unless otherwise indicated, all nucleic acid sequences are written left to right in 5' to 3' orientation; amino acid sequences are written left to right in amino to carboxy orientation, respectively.

[0437] The headings provided herein are not limitations of the various aspects or embodiments of the disclosure that may be incorporated by reference in their entirety. Accordingly, the terms defined immediately below are more fully defined by reference to the specification as a whole.

[0438] Amino acids are described herein using the name, three-letter abbreviation, or one-letter abbreviation of the amino acid. The term "protein" as used herein includes proteins, polypeptides, and peptides. As used herein, the term "amino acid sequence" is synonymous with the term "polypeptide" and / or the term "protein". In some cases, the term "amino acid sequence" is synonymous with the term "peptide". In some cases, the term "amino acid sequence" is synonymous with the term "enzyme".

[0439] In the present disclosure and claims, conventional one-letter and three-letter codes for amino acid residues may be used. The three-letter codes for amino acids are as defined according to the IUPACIUB Joint Commission on Biochemical Nomenclature (JCBN). It is also understood that due to the degeneracy of the genetic code, a polypeptide may be coded for by more than one nucleotide sequence.

[0440] Other definitions of terms can be found throughout the specification.Before describing exemplary embodiments in more detail, it should be understood that the present disclosure is not limited to the specific embodiments described, and therefore can of course vary.It is also understood that the terminology used herein is for the purpose of describing specific embodiments only, and is not intended to be limiting, since the scope of the present disclosure is limited only by the appended claims.

[0441] Where a range of values ​​is provided, each intervening value, to the tenth of the unit of the lower limit, between the upper and lower limits of that range is also specifically disclosed unless the context clearly indicates otherwise. Each smaller range between any stated or intervening value in a stated range and any other stated or intervening value in that stated range is encompassed in the disclosure. The upper and lower limits of these smaller ranges may be independently included or excluded from the range, and each range that includes either limit, does not include either limit, or includes both limits within that smaller range, subject to any specifically excluded limit in the stated range, is also encompassed in the disclosure. Where a stated range includes one or both of the limits, ranges excluding either or both of the included limits are also included in the disclosure.

[0442] It must be noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural references unless the context clearly indicates otherwise. Thus, for example, reference to an "enzyme" or "galactose-1-phosphate uridyl transferase" includes a plurality of such candidate substances known to those of skill in the art and equivalents thereof, and so forth.

[0443] advantage Surprisingly, it has been found that by modulating the activity or expression of galactose-1-phosphate uridyltransferase as taught herein, which acts as a positive regulator of alkaloid content in tobacco, it is possible to modulate the alkaloid and / or TSNA precursor content of the plant, thereby producing tobacco industry products that have modulated (e.g., reduced) alkaloid content and / or reduced TSNA precursor content and commercially desirable traits desired by consumers of tobacco industry products.

[0444] The present inventors have surprisingly determined a method for regulating the alkaloid content and / or TSNA precursor content of a plant (e.g., a tobacco plant) by regulating the activity or expression of galactose-1-phosphate uridyltransferase. The alkaloid or TSNA precursor content of a plant (e.g., a tobacco plant) can be reduced by reducing or inhibiting the activity or expression of galactose-1-phosphate uridyltransferase as described herein. Prior to the present invention, it was not known that the activity or expression of galactose-1-phosphate uridyltransferase as described herein can be used to regulate the alkaloid and / or TSNA precursor content of a plant (e.g., a tobacco plant).

[0445] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application, and nothing herein is to be construed as an admission that such publications constitute prior art to the claims appended hereto. [Example] EXAMPLES

[0446] “Virus-induced gene silencing (VIGS) of Nitab4.5_0002825g0060.2 reduces alkaloid content in leaves” Virus-induced gene silencing (VIGS) For virus-induced gene silencing, a 300 nucleotide cDNA fragment of Nitab4.5_0002825g0060.2: TGTGATATTCAACCAAATGAATTGTTAATTGATCAATCAGCCCATTTCATATCATTGGTTCCCTTTGCTGCAACTTTTGCTTTTGAGATTTGGATAATTCCTCGTGATCACTCCTCTCATTTTCATGAACTCGATAATGAAAAGGCAAAT GATCTTGGAGGGTTGTTGAAACTCATGCTTTTGAAGATGTCTTTGCAGTTGAACAATCCACCATTCAACCTCCTTATTCATACCTCCCCATTTCAAGTAGATCCCTCATATGCTCCTTCCACACACTGGTTTTTACAAATAGCTCCCCAT (TRV2: SEQ ID NO: 16) was synthesized and cloned into pTV00 (between the EcoRI and XhoI sites) using the In-Fusion cloning kit. The plasmid was then transformed into A. tumefaciens GV3101.

[0447] Both TRV vectors containing the target nucleotide sequence (TRV RNA1, SEQ ID NO:15) and (TRV RNA2) were grown separately in A. tumefaciens. These cultures were mixed (1:1) and syringe infiltrated into 2-week-old TN90 plants. Silencing efficacy was assessed by evaluating the expression levels of the target genes 5 weeks after virus infection.

[0448] Silencing VIGS assays were performed as previously described (Ratcliff et al., 2001) Ratcliff, F et al., (2001), The Plant Journal, 25: 237-245 (hereby incorporated by reference). Briefly, independent cultures of A. tumefaciens GV3101 harboring the TRV2 and TRV1 plasmids were grown overnight in LB medium supplemented with the appropriate antibiotics. Cultures were resuspended in VIGS buffer (10 mM morpholineethanesulfonic acid, pH 5.6, 10 mM MgCL2, and 100 μM acetocyringone) and optical density was measured at OD 600 The cultures were adjusted to 0.05% CI = 1 and incubated overnight at room temperature in the dark. These cultures were mixed (1:1) and syringe infiltrated into 2-week-old TN90 plants. Silencing efficacy was assessed by evaluating the expression levels of the target genes 2 weeks after virus infection. TRV-luciferase was used as a negative control and TRV-PDS (reduced chlorophyll content in silenced leaves) was used as a phenotypic silencing control.

[0449] Alkaloid determination The relative content of pyridine alkaloids was determined by reversed-phase high performance liquid chromatography with tandem mass spectrometry (LC-MS / MS). Chromatographic separation was performed using a Gemini-NX column (100 mm x 3.0 mm, 3 μm particle size, Phenomenex), and gradient chromatographic separation was performed using 6.5 mM ammonium acetate buffer (aq) (pH 10) and methanol.

[0450] The mass spectrometer was operated in electrospray (ESI) positive mode using scheduled MRM data acquisition. Two MRM transitions were monitored for each analyte and one for the isotopically labeled internal standard.

[0451] [Table 5]

[0452] result Alkaloid content of plants targeted with VIGS constructs from Nitab4.5_0002825g0060.2. Graphs are representative of two biological replicates (N=12) analyzed by one-way ANOVA and Tukey's multiple comparison post-hoc test. Values ​​are shown as mean ± SEM. Asterisks indicate statistical significance with P values ​​of 0.05 or less.

[0453] VIGS of Nitab4.5_0002825g0060.2 resulted in a reduction in the alkaloid content in the leaves, in particular the content of nicotine, nornicotine and PON.

[0454] conclusion Nitab4.5_0002825g0060.2 is a positive regulator of alkaloid content in tobacco, especially in leaves, and is a regulator of pyridine alkaloids. EXAMPLES

[0455] "Nitab4.5_0002825g0060.2 has functional galactose-1-phosphate uridyltransferase activity" We characterized Nitab4.5_0002825g0060.2 as a gene encoding galactose-1-phosphate uridyltransferase, an enzyme that promotes the simultaneous conversion of uridine diphosphoglucose (UDP-glucose) and galactose-1-phosphate (gal-1P) to uridine diphosphogalactose (UDP-galactose) and glucose-1-phosphate.

[0456] To confirm the classification, functional assays were performed to determine the activity of Nitab4.5_0002825g0060.2.

[0457] The activity of Nitab4.5_0002825g0060.2 was functionally verified and measured using the galactose-1-phosphate uridyltransferase coupling assay protocol described in Mayes and Hanson, supra. The coupling assay results in the formation of β-NADPH, which is monitored by an increase in absorbance at 340 nm.

[0458] Coupling Enzyme Reaction: [ka]

[0459] result FIG. 2 shows the measured endpoint absorbance values ​​(340 nm) for the production of β-NADPH over a 60 minute reaction with 1.7 μg Nitab4.5_0002825g0060.2 enzyme or 0.5 μg positive control enzyme (recombinant human galactose-1-phosphate uridyltransferase, MyBiosource, MBS143204) in the presence of 0.67 mM uridine 5'-diphosphoglucose and 1.3 mM galactose 1-phosphate. The results of the control reactions are also shown on the same graph, showing that the reaction is dependent on uridine 5'-diphosphoglucose and galactose 1-phosphate. Both the MBP and no enzyme controls have limited activity. The commercial positive control shows >5-fold higher activity per microgram of protein in this assay, while the Nitab4.5_0002825g0060.2 enzyme shows reliable substrate-dependent activity. Error bars are standard deviations from four replicates.

[0460] conclusion Nitab4.5_0002825g0060.2 can function as a galactose-1-phosphate uridyltransferase and, as shown in Example 1, is a positive regulator of alkaloid content in tobacco, particularly in leaves, and is a regulator of pyridine alkaloids. EXAMPLES

[0461] "Homolog Test" The effect of homologues of SEQ ID NO:3, ie, those listed in Table 1, is tested in the assays described in the Examples above.

Claims

1. 1. A method for modulating (e.g., reducing) the alkaloid content of a tobacco plant or part thereof, or a tobacco plant cell, comprising modifying the plant or plant cell by modulating (e.g., reducing) the activity or expression of galactose-1-phosphate uridyltransferase.

2. 1. A method for modulating (e.g., decreasing) the content of tobacco-specific nitrosamines (TSNAs) or precursors of TSNAs in a tobacco plant or plant part thereof, or a tobacco plant cell, comprising modifying the plant or plant cell by modulating (e.g., decreasing) the activity or expression of galactose-1-phosphate uridyltransferase.

3. 1. A method for producing a plant or part thereof, cell or cell culture, plant propagation material, leaf, cut harvested leaf, treated leaf, or cut treated leaf having modulated (e.g., reduced) alkaloid content, the method comprising modifying the plant or cell culture to modulate activity or expression of galactose-1-phosphate uridyltransferase.

4. Use of at least one gene encoding galactose-1-phosphate uridyltransferase for modulating the alkaloid content of tobacco cells or tobacco plants or parts thereof.

5. Galactose-1-phosphate uridyltransferase a) comprising the amino acid sequence shown in SEQ ID NO: 3, or a functional variant or a functional fragment or an orthologue of SEQ ID NO: 3, or a sequence having at least 80% identity to SEQ ID NO: 3, or a homologue of SEQ ID NO: 3, or b) encoded by the nucleotide sequence shown in SEQ ID NO: 1 or 2, or a functional variant or a functional fragment or an orthologue of SEQ ID NO: 1 or 2, or a nucleic acid sequence having at least 80% identity to SEQ ID NO: 1 or 2, or a homologue of SEQ ID NO: 1 or 2; The method or use according to any one of claims 1 to 4.

6. 6. The method or use according to any one of claims 1 to 5, wherein the alkaloid content is modulated (e.g. reduced) compared to a plant or cell culture that has not been modified to modulate the activity or expression of galactose-1-phosphate uridyltransferase.

7. A tobacco plant or part thereof, or a tobacco cell or cell culture, which has been modified to modulate (e.g., decrease) the activity or expression of galactose-1-phosphate uridyltransferase, and which has a reduced content of alkaloids and / or TSNA precursors compared to an unmodified plant or unmodified cell or cell culture.

8. Plant propagation material obtainable (eg obtained) from a plant according to claim 7 or from a plant or a cell or cell culture produced by the method or use according to any of claims 1 to 6.

9. 9. The method or use according to any one of claims 1 to 6, or the plant or part thereof, or cell or cell culture according to claim 7, or the plant propagation material according to claim 8, wherein the alkaloid content of the plant is reduced compared to a plant or cell culture that has not been modified to modulate the activity or expression of galactose-1-phosphate uridyltransferase.

10. 10. A method or use according to any one of claims 1 to 6 and 9, a tobacco plant or part thereof or a tobacco cell or cell culture according to claim 7 or 9, or a plant propagation material according to claim 8, in which the content of one or more alkaloids selected from nicotine, nornicotine, PON, anabasine, myosmine and anatabine is regulated (e.g. reduced), preferably the content of nicotine, nornicotine and / or PON is regulated (e.g. reduced).

11. 11. The method or use of claim 10, a tobacco plant or part thereof, or a tobacco cell or tobacco cell culture according to claim 10, or a plant propagation material according to claim 10, which has a reduced nicotine content.

12. Use of a tobacco plant or part thereof, or a tobacco cell or cell culture, according to any one of claims 7 and 9 to 11, or a plant produced by the method according to any one of claims 1 to 6 and 9 to 11, for breeding plants.

13. 12. Use of a tobacco plant or part thereof, or a tobacco cell or cell culture, according to any one of claims 7 and 9 to 11, or a plant produced by the method according to any one of claims 1 to 6 and 9 to 11, for the manufacture of a product.

14. Use of a tobacco plant or part thereof according to any one of claims 7 and 9 to 11, or a plant produced by the method according to any one of claims 1 to 6 and 9 to 11, for producing a crop.

15. Use of a tobacco plant or part thereof according to any one of claims 7 and 9 to 11, or a plant produced by the method according to any one of claims 1 to 6 and 9 to 11, for the production of leaves.

16. Harvested leaves of a plant according to any one of claims 7 and 9 to 11, or obtainable from a plant propagated from the propagation material according to any one of claims 8 to 11, or obtainable from a plant obtained by the use according to any one of claims 4 to 6 and 9 to 11, or obtainable from a plant produced by the method according to any one of claims 1 to 6 and 9 to 11.

17. 17. Harvested leaves of the plant of claim 16, which are cut harvested leaves.

18. obtainable (e.g. obtained) from a plant obtainable from the use according to any one of claims 4 to 6 and 9 to 11; or which are obtainable (e.g. obtained) by treating a plant according to any one of claims 7 and 9 to 11; obtainable (e.g. obtained) from a plant propagated from a plant propagation material according to any one of claims 8 to 11; or obtainable (e.g. obtained) by processing harvested leaves of a plant according to claim 16 or 17; or Obtainable (e.g. obtained) from a plant produced by the method according to any one of claims 1 to 6 and 9 to 11. Treated leaves, preferably treated tobacco leaves, preferably treated non-viable tobacco leaves.

19. 20. The treated leaves of claim 18, wherein the leaves are treated by drying, fermenting, pasteurizing or a combination thereof.

20. The treated leaves according to claim 18 or 19, which are cut treated leaves.

21. A dried tobacco material made from a plant or part thereof according to any one of claims 7 and 9 to 11, or from harvested leaves according to claims 16 or 17, or from treated leaves according to any one of claims 18 to 20.

22. 22. A tobacco blend comprising the dry tobacco material of claim 21.

23. A tobacco plant or a part thereof, or a tobacco cell or cell culture according to any one of claims 7 and 9 to 11, A tobacco plant or part thereof propagated from the tobacco plant propagation material of claim 8. Harvested leaves of the plant according to claim 16 or 17. The treated leaves according to any one of claims 18 to 20. Tobacco industry products prepared from.

24. 24. The tobacco industry product of claim 23, which is a combustible smoking article.

25. 24. The tobacco industry product of claim 23 which is a smokeless tobacco product.

26. 24. The tobacco product of claim 23, which is a non-combustible aerosol delivery system, such as a tobacco heating device or an aerosol generating device.

27. A combustible smoking article, a non-combustible aerosol delivery system, a smokeless tobacco product, or a tobacco heating device comprising a plant or part thereof or an extract thereof (e.g., a tobacco extract) according to any one of claims 7 and 9 to 11, or a tobacco cell culture according to any one of claims 7 and 9 to 11, or a dried tobacco material according to claim 21, or a tobacco blend according to claim 22.

28. 2. Use of a nucleotide sequence encoding a galactose-1-phosphate uridyltransferase for the selection of plants having a modulated (e.g., reduced) alkaloid content and / or a modulated (e.g., reduced) TSNA or TSNA precursor content, the nucleotide sequence comprising: a) encoding the amino acid sequence shown in SEQ ID NO: 3, or a functional variant or a functional fragment or an orthologue of SEQ ID NO: 3, or a sequence having at least 80% identity to SEQ ID NO: 3, or a homologue of SEQ ID NO: 3, or b) comprising a sequence as set forth in SEQ ID NO: 1 or 2, or a functional variant or a functional fragment or an orthologue of SEQ ID NO: 1 or 2, or a nucleic acid sequence having at least 80% identity to SEQ ID NO: 1 or 2, or a homologue of SEQ ID NO: 1 or 2; The above uses.

29. a) encoding the amino acid sequence shown in SEQ ID NO: 3, or a functional variant or a functional fragment or an orthologue of SEQ ID NO: 3, or a sequence having at least 80% identity to SEQ ID NO: 3, or a homologue of SEQ ID NO: 3, or b) comprising a sequence as set forth in SEQ ID NO: 1 or 2, or a functional variant or a functional fragment or an orthologue of SEQ ID NO: 1 or 2, or a nucleic acid sequence having at least 80% identity to SEQ ID NO: 1 or 2, or a homologue of SEQ ID NO: 1 or 2 A plant mutant carrying a genetic variation in a nucleotide sequence, The genetic mutation modulates (e.g., decreases) the activity or expression of galactose-1-phosphate uridyltransferase, and the mutant plant has a modulated (e.g., decreased) alkaloid content and / or a modulated tobacco specific nitrosamine (TSNA) or TSNA precursor content compared to a comparable plant that does not carry the genetic mutation.

30. 30. Progeny or seed of a mutant plant carrying the genetic mutation of claim 29.

31. a) encoding the amino acid sequence shown in SEQ ID NO: 3, or a functional variant or a functional fragment or an orthologue of SEQ ID NO: 3, or a sequence having at least 80% identity to SEQ ID NO: 3, or a homologue of SEQ ID NO: 3, or b) comprising a sequence as set forth in SEQ ID NO: 1 or 2, or a functional variant or a functional fragment or an orthologue of SEQ ID NO: 1 or 2, or a nucleic acid sequence having at least 80% identity to SEQ ID NO: 1 or 2, or a homologue of SEQ ID NO: 1 or 2 1. Harvested leaf, processed leaf, or cured tobacco material produced from a plant containing an alteration in a nucleotide sequence, The harvested leaves, processed leaves, or cured tobacco material, wherein the modification modulates (e.g., decreases) the activity or expression of galactose-1-phosphate uridyltransferase, and the plant has a modulated (e.g., decreased) alkaloid content and / or a modulated tobacco-specific nitrosamine (TSNA) or precursor of TSNA content, compared to a comparable plant that does not possess the modification in the galactose-1-phosphate uridyltransferase.

Images